Istradefylline    B-Purine114706749
(    O
KW-6002    O
)    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
monoterpenol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
monoterpenol    O
acetate    O
ester    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
N6-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N6-acetyl    O
-    O
N6-hydroxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
N    O
-    O
acetylneuraminate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N    O
-    O
acetyl-4-O    O
-    O
acetylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
N    O
-    O
acetylneuraminate    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    O
,    O
N    O
-    O
acetyl-7-O    O
-    O
acetylneuraminate    O
,    O
and    O
N    O
-    O
acetyl-9-O    O
-    O
acetylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
N    O
-    O
hydroxyarylamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N    O
-    O
acetoxyarylamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
peptide    O
,    O
whereas    O
its    O
two    O
products    O
are    O
Nalpha    O
-    O
acetylpeptide    O
and    O
CoA.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
L    O
-    O
phenylalanine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
phenylalanine    O
.    O

The    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
acetyl    O
phosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
alpha-2,8-linked    O
polymer    O
of    O
sialic    O
acid    O
,    O
whereas    O
its    O
3    O
products    O
are    O
CoA    O
,    O
polysialic    O
acid    O
acetylated    O
on    O
O-7    O
,    O
and    O
polysialic    O
acid    O
acetylated    O
on    O
O-9    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
ribosomal    O
-    O
protein    O
L    O
-    O
alanine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
ribosomal    O
-    O
protein    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
alanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
salutaridinol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
7-O    O
-    O
acetylsalutaridinol    O
.    O

:    O
acetyl-CoA    B-Purine114706749
+    O
L    O
-    O
serine    O
CoA    O
+    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
serine    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
L    O
-    O
serine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
serine    O
.    O

More    O
specifically    O
,    O
its    O
role    O
is    O
to    O
catalyse    O
the    O
activation    O
of    O
L    O
-    O
serine    O
by    O
acetyl-CoA    B-Purine114706749
entry    O
refers    O
to    O
the    O
N    O
-    O
terminus    O
of    O
the    O
protein    O
which    O
has    O
a    O
sequence    O
that    O
is    O
conserved    O
in    O
plants    O
and    O
bacteria    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
taxa-4(20),11-dien-5alpha    O
-    O
ol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
taxa-4(20),11-dien-5alpha    O
-    O
yl    O
acetate    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
,    O
(    O
S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate    O
,    O
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
L-2-acetamido-6-oxoheptanedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
2-aminoethanethiol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
S-(2-aminoethyl)thioacetate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
and    O
16-epivellosimine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
vinorine    O
.    O

Arsenic    O
interferes    O
with    O
cellular    O
longevity    O
by    O
allosteric    O
inhibition    O
of    O
an    O
essential    O
metabolic    O
enzyme    O
pyruvate    O
dehydrogenase    O
(    O
PDH    O
)    O
complex    O
,    O
which    O
catalyzes    O
the    O
oxidation    O
of    O
pyruvate    O
to    O
acetyl-CoA    B-Purine114706749
by    O
NAD+    O
.    O

PDH    O
is    O
a    O
precursor    O
of    O
acetyl-CoA    B-Purine114706749
,    O
thus    O
the    O
inhibition    O
of    O
PDH    O
eventually    O
limits    O
the    O
production    O
of    O
ATP    O
in    O
electron    O
transport    O
chain    O
,    O
as    O
well    O
as    O
the    O
production    O
of    O
gluconeogenesis    O
intermediates    O
.    O

However    O
,    O
an    O
understanding    O
of    O
the    O
physiology    O
of    O
the    O
organism    O
would    O
have    O
revealed    O
that    O
due    O
to    O
an    O
incomplete    O
tricarboxylic    O
acid    O
pathway    O
,    O
"    O
Lactobacillus    O
plantarum    O
"    O
does    O
not    O
actually    O
produce    O
succinyl    O
-    O
CoA    O
,    O
and    O
the    O
correct    O
reactant    O
for    O
that    O
part    O
of    O
the    O
reaction    O
was    O
acetyl-CoA    B-Purine114706749

In    O
contrast    O
the    O
"    O
Rhizobium    O
etli    O
"    O
,    O
tetramer    O
in    O
complex    O
with    O
ethyl    O
-    O
CoA    O
,    O
a    O
non    O
-    O
hydrolyzable    O
analog    O
of    O
acetyl-CoA    B-Purine114706749
,    O
possesses    O
only    O
one    O
line    O
of    O
symmetry    O
.    O

In    O
most    O
species    O
,    O
this    O
reaction    O
requires    O
acetyl-CoA    B-Purine114706749
as    O
an    O
allosteric    O
activator    O
binding    O
to    O
the    O
PT    O
domain    O
.    O

Next    O
,    O
a    O
series    O
of    O
condensation    O
reactions    O
of    O
three    O
acetate    O
units    O
from    O
malonyl    O
-    O
CoA    O
occurs    O
,    O
each    O
proceeding    O
through    O
an    O
acetyl-CoA    B-Purine114706749
carbanion    O
derived    O
from    O
malonyl    O
-    O
CoA    O
decarboxylation    O
.    O

In    O
this    O
pathway    O
,    O
two    O
molecules    O
of    O
acetyl-CoA    B-Purine114706749
undergo    O
a    O
condensation    O
reaction    O
to    O
give    O
acetoacetyl    O
-    O
CoA.    O
This    O
product    O
then    O
condenses    O
with    O
third    O
molecule    O
of    O
acetyl    O
-    O
CoA    O
in    O
a    O
stereospecific    O
fashion    O
to    O
form    O
3-hydroxy-3-methylglutaryl    O
-    O
CoA    O
(    O
HMG    O
-    O
CoA    O
)    O
which    O
then    O
is    O
reduced    O
to    O
mevalonic    O
acid    O
(    O
MVA    O
)    O
.    O

The    O
backbone    O
is    O
synthesized    O
through    O
the    O
addition    O
of    O
two    O
carbon    O
units    O
via    O
addition    O
of    O
acetate    O
units    O
from    O
acetyl-CoA    B-Purine114706749
The    O
5    O
methyl    O
groups    O
are    O
added    O
via    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
(    O
SAM    O
)    O
methylation    O
,    O
as    O
opposed    O
to    O
incorporation    O
of    O
propionate    O
(    O
instead    O
of    O
acetate    O
)    O
to    O
the    O
growing    O
compound    O
during    O
biosynthesis    O
.    O

IPP    O
is    O
formed    O
from    O
acetyl-CoA    B-Purine114706749
via    O
the    O
intermediacy    O
of    O
mevalonic    O
acid    O
in    O
the    O
HMG    O
-    O
CoA    O
reductase    O
pathway    O
.    O

The    O
pyruvate    O
is    O
then    O
converted    O
into    O
acetyl-CoA    B-Purine114706749
so    O
that    O
it    O
can    O
enter    O
the    O
TCA    O
cycle    O
and    O
convert    O
the    O
original    O
pyruvate    O
molecules    O
into    O
ATP    O
,    O
or    O
usable    O
energy    O
for    O
the    O
organism    O
.    O

Each    O
pyruvate    O
goes    O
through    O
a    O
series    O
of    O
reactions    O
that    O
converts    O
it    O
to    O
acetyl    B-Purine114706749
coenzyme    I-Purine114706749
A    I-Purine114706749

In    O
the    O
presence    O
of    O
air    O
and    O
various    O
cofactors    O
and    O
enzymes    O
,    O
fatty    O
acids    O
are    O
degraded    O
to    O
acetyl-CoA    B-Purine114706749
The    O
pathway    O
is    O
called    O
beta    O
-    O
oxidation    O
.    O

Enoyl    O
-    O
CoA    O
hydratase    O
is    O
an    O
enzyme    O
that    O
hydrates    O
the    O
double    O
bond    O
between    O
the    O
second    O
and    O
third    O
carbons    O
on    O
acyl    O
-    O
CoA.    O
This    O
enzyme    O
,    O
also    O
known    O
as    O
crotonase    O
,    O
is    O
essential    O
to    O
metabolizing    O
fatty    O
acids    O
to    O
produce    O
both    O
acetyl    B-Purine114706749
CoA    I-Purine114706749
and    O
energy    O
.    O

ATP    O
citrate    O
lyase    O
is    O
the    O
primary    O
enzyme    O
responsible    O
for    O
the    O
synthesis    O
of    O
cytosolic    O
acetyl-CoA    B-Purine114706749
in    O
many    O
tissues    O
.    O

ATP    O
-    O
citrate    O
lyase    O
is    O
responsible    O
for    O
catalyzing    O
the    O
conversion    O
of    O
citrate    O
and    O
CoA    O
into    O
acetyl-CoA    B-Purine114706749
and    O
oxaloacetate    O
,    O
along    O
with    O
the    O
hydrolysis    O
of    O
ATP    O
.    O

In    O
the    O
presence    O
of    O
ATP    O
and    O
Coenzyme    O
A    O
,    O
citrate    O
lyase    O
catalyzes    O
the    O
cleavage    O
of    O
citrate    O
to    O
yield    O
acetyl    B-Purine114706749
CoA    I-Purine114706749
,    O
oxaloacetate    O
,    O
ADP    O
,    O
and    O
orthophosphate    O
:    O

:    O
citrate    O
+    O
ATP    O
+    O
CoA    O
+    O
H2O    O
→    O
oxaloacetate    O
+    O
Acetyl-CoA    B-Purine114706749
+    O
ADP    O
+    O
Pi    O

The    O
first    O
three    O
steps    O
of    O
the    O
reaction    O
pathways    O
lead    O
from    O
ethanol    O
to    O
acetaldehyde    O
to    O
acetic    O
acid    O
to    O
acetyl-CoA    B-Purine114706749
Once    O
acetyl    O
-    O
CoA    O
is    O
formed    O
,    O
it    O
is    O
free    O
to    O
enter    O
directly    O
into    O
the    O
citric    O
acid    O
cycle    O
.    O

Two    O
enzymes    O
are    O
associated    O
with    O
the    O
conversion    O
of    O
acetic    O
acid    O
to    O
acetyl-CoA    B-Purine114706749
The    O
first    O
is    O
acyl    O
-    O
CoA    O
synthetase    O
short    O
-    O
chain    O
family    O
member    O
2    O
ACSS2    O
(    O
EC    O
6.2.1.1    O
)    O
.    O

It    O
is    O
created    O
from    O
acetyl-CoA    B-Purine114706749
,    O
a    O
thioester    O
,    O
which    O
reacts    O
with    O
the    O
enolate    O
of    O
a    O
second    O
molecule    O
of    O
acetyl    O
-    O
CoA    O
in    O
a    O
Claisen    O
condensation    O
reaction    O
,    O
and    O
it    O
is    O
acted    O
upon    O
by    O
HMG    O
-    O
CoA    O
synthase    O
to    O
form    O
HMG    O
-    O
CoA.    O
During    O
the    O
metabolism    O
of    O
leucine    O
,    O
this    O
last    O
reaction    O
is    O
reversed    O
.    O

Thiolases    O
,    O
also    O
known    O
as    O
acetyl    O
-    O
coenzyme    O
A    O
acetyltransferases    O
(    O
ACAT    O
)    O
,    O
are    O
enzymes    O
which    O
convert    O
two    O
units    O
of    O
acetyl-CoA    B-Purine114706749
to    O
acetoacetyl    O
CoA    O
in    O
the    O
mevalonate    O
pathway    O
.    O

This    O
gene    O
encodes    O
a    O
mitochondrially    O
localized    O
enzyme    O
that    O
catalyzes    O
the    O
reversible    O
formation    O
of    O
acetoacetyl    O
-    O
CoA    O
from    O
two    O
molecules    O
of    O
acetyl-CoA    B-Purine114706749
The    O
ACAT1    O
enzyme    O
has    O
a    O
few    O
unique    O
properties    O
.    O

The    O
compound    O
undergoes    O
beta    O
oxidation    O
,    O
forming    O
one    O
or    O
more    O
molecules    O
of    O
acetyl-CoA    B-Purine114706749
This    O
,    O
in    O
turn    O
,    O
enters    O
the    O
citric    O
acid    O
cycle    O
,    O
eventually    O
forming    O
several    O
molecules    O
of    O
ATP    O
.    O

Acetyl-CoA    B-Purine114706749

The    O
complex    O
acts    O
to    O
convert    O
pyruvate    O
(    O
a    O
product    O
of    O
glycolysis    O
in    O
the    O
cytosol    O
)    O
to    O
acetyl-coA    B-Purine114706749
,    O
which    O
is    O
then    O
oxidized    O
in    O
the    O
mitochondria    O
to    O
produce    O
energy    O
,    O
in    O
the    O
citric    O
acid    O
cycle    O
.    O

Pyruvate    O
dehydrogenase    O
kinase    O
is    O
activated    O
by    O
ATP    O
,    O
NADH    O
and    O
acetyl-CoA    B-Purine114706749
It    O
is    O
inhibited    O
by    O
ADP    O
,    O
NAD+    O
,    O
CoA    O
-    O
SH    O
and    O
pyruvate    O
.    O

Processing    O
of    O
cholesterol    O
and    O
protein    O
gives    O
propionyl    O
-    O
CoA    O
that    O
is    O
converted    O
to    O
methylmalonyl-CoA    B-Purine114706749
,    O
which    O
is    O
used    O
by    O
MUT    O
enzyme    O
to    O
make    O
succinyl    O
-    O
CoA.    O
Vitamin    O
is    O
needed    O
to    O
prevent    O
anemia    O
,    O
since    O
making    O
porphyrin    O
and    O
heme    O
in    O
mitochondria    O
for    O
producing    O
hemoglobin    O
in    O
red    O
blood    O
cells    O
depends    O
on    O
succinyl    O
-    O
CoA    O
made    O
by    O
vitamin    O
.    O

The    O
4    O
substrates    O
of    O
this    O
enzyme    O
are    O
acyl    O
-    O
CoA    O
,    O
methylmalonyl-CoA    B-Purine114706749
,    O
NADPH    O
,    O
and    O
H+    O
,    O
whereas    O
its    O
4    O
products    O
are    O
multi    O
-    O
methyl    O
-    O
branched    O
acyl    O
-    O
CoA    O
,    O
CoA    O
,    O
CO2    O
,    O
and    O
NADP+    O
.    O

D.    O
propionicus    O
"    O
uses    O
the    O
methylmalony-CoA    B-Purine114706749
pathway    O
to    O
ferment    O
3    O
moles    O
of    O
pyruvate    O
to    O
2    O
moles    O
of    O
acetate    O
and    O
1    O
mole    O
of    O
propionate    O
.    O

Vidarabine    B-Purine114706749
or    O
9-β-D-arabinofuranosyladenine    B-Purine114706749
(ara-A)    I-Purine114706749
is    O
an    O
antiviral    O
drug    O
which    O
is    O
active    O
against    O
herpes    O
simplex    O
and    O
varicella    O
zoster    O
viruses    O
.    O

Vidarabine    B-Purine114706749

File    O
:    O
Vidarabine    B-Purine114706749

8-Oxo-2'-deoxyguanosine    B-Purine114706749

DNA    O
damage    O
is    O
an    O
alteration    O
in    O
the    O
chemical    O
structure    O
of    O
DNA    O
,    O
such    O
as    O
a    O
break    O
in    O
a    O
strand    O
of    O
DNA    O
,    O
a    O
base    O
missing    O
from    O
the    O
backbone    O
of    O
DNA    O
,    O
or    O
a    O
chemically    O
changed    O
base    O
as    O
8-OHdG    B-Purine114706749

A    O
marker    O
of    O
DNA    O
oxidation    O
,    O
8-Oxo-2'-deoxyguanosine    B-Purine114706749
,    O
has    O
been    O
found    O
to    O
be    O
increased    O
in    O
both    O
the    O
plasma    O
and    O
urine    O
of    O
depressed    O
patients    O
.    O

(    O
see    O
e.g.    O
8-Oxo-2'-deoxyguanosine    B-Purine114706749
)    O

Regadenoson    B-Purine114706749
(    O
brand    O
name    O
"    O
Lexiscan    O
"    O
)    O
,    O
which    O
acts    O
specifically    O
at    O
the    O
adenosine    O
A2A    O
receptor    O
,    O
thus    O
affecting    O
the    O
heart    O
more    O
than    O
the    O
lung    O
.    O

Following    O
this    O
,    O
myocardial    O
stress    O
is    O
induced    O
,    O
either    O
by    O
exercise    O
or    O
pharmacologically    O
with    O
adenosine    O
,    O
dobutamine    O
or    O
dipyridamole(Persantine    O
)    O
,    O
which    O
increase    O
the    O
heart    O
rate    O
or    O
by    O
regadenoson    B-Purine114706749
)    O
,    O
a    O
vasodilator    O
.    O

M    O
-    O
Ras    O
shares    O
a    O
similar    O
structure    O
with    O
H    O
-    O
Ras    O
and    O
Rap2A    O
with    O
the    O
exception    O
of    O
its    O
switch    O
1    O
conformation    O
when    O
bound    O
to    O
guanosine    O
5'-(beta    O
,    O
gamma    O
-    O
imido)triphosphate    O
(    O
Gpp(NH)p    B-Purine114706749
)    O
.    O

Adenophostin    B-Purine114706749
A    O
is    O
a    O
potent    O
inositol    O
triphosphate    O
(    O
IP3    O
)    O
receptor    O
agonist    O
,    O
but    O
is    O
much    O
more    O
potent    O
than    O
IP3    O
.    O

In    O
1976    O
a    O
bacteriophage    O
-    O
S-2L    O
-    O
which    O
infects    O
species    O
of    O
the    O
genus    O
"    O
Synechocystis    O
"    O
was    O
found    O
to    O
have    O
all    O
the    O
adenosine    O
bases    O
within    O
its    O
genome    O
replaced    O
by    O
2,6-diaminopurine    B-Purine114706749
.    O

Mice    O
also    O
show    O
a    O
decrease    O
in    O
FAM185a    O
expression    O
in    O
tissues    O
that    O
have    O
been    O
treated    O
with    O
Reversine    B-Purine114706749
,    O
indicating    O
the    O
protein    O
's    O
potential    O
role    O
relates    O
to    O
stem    O
cell    O
differentiation    O
during    O
development    O
.    O

The    O
enzyme    O
adenylosuccinate    O
synthase    O
carries    O
out    O
the    O
reaction    O
by    O
the    O
addition    O
of    O
aspartate    O
to    O
IMP    O
and    O
requires    O
the    O
input    O
of    O
energy    O
from    O
a    O
phosphoanhydride    O
bond    O
in    O
the    O
form    O
of    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
(    O
GTP    O
)    O
.    O

In    O
molecular    O
biology    O
,    O
Adenylosuccinate    O
synthase    O
(    O
or    O
adenylosuccinate    O
synthetase    O
)    O
is    O
an    O
enzyme    O
that    O
plays    O
an    O
important    O
role    O
in    O
purine    O
biosynthesis    O
,    O
by    O
catalysing    O
the    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
(    O
GTP)-dependent    O
conversion    O
of    O
inosine    B-Purine114706749
monophosphate    I-Purine114706749
(    O
IMP    O
)    O
and    O
aspartic    O
acid    O
to    O
guanosine    B-Purine114706749
diphosphate    I-Purine114706749
(    O
GDP    O
)    O
,    O
phosphate    O
and    O
N(6)-(1,2-dicarboxyethyl)-AMP    O
.    O

The    O
Gs    O
alpha    O
subunit    O
of    O
the    O
stimulated    O
G    O
protein    O
complex    O
exchanges    O
GDP    B-Purine114706749
for    O
GTP    B-Purine114706749
and    O
is    O
released    O
from    O
the    O
complex    O
.    O

It    O
also    O
allows    O
high    O
energy    O
molecules    O
to    O
form    O
;    O
3x    O
NADH    O
,    O
FADH2    O
,    O
and    O
GTP    B-Purine114706749
/    O
ATP    O
are    O
all    O
produced    O
by    O
one    O
iteration    O
of    O
the    O
cycle    O
.    O

This    O
gene    O
encodes    O
a    O
mitochondrial    O
enzyme    O
that    O
catalyzes    O
the    O
conversion    O
of    O
oxaloacetate    O
(    O
OAA    O
)    O
to    O
phosphoenolpyruvate    O
(    O
PEP    O
)    O
in    O
the    O
presence    O
of    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
(    O
GTP    O
)    O
.    O

When    O
the    O
50S    O
subunit    O
joins    O
,    O
it    O
hydrolyzes    O
GTP    B-Purine114706749
to    O
GDP    B-Purine114706749
and    O
Pi    O
,    O
causing    O
a    O
conformational    O
change    O
in    O
the    O
IF2    O
that    O
causes    O
IF2    O
to    O
release    O
and    O
allow    O
the    O
70S    O
subunit    O
to    O
form    O
.    O

The    O
biosynthesis    O
of    O
molybdopterin    O
begins    O
with    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
.    O

Substrate    O
-    O
level    O
phosphorylation    O
is    O
a    O
metabolic    O
reaction    O
that    O
results    O
in    O
the    O
formation    O
of    O
ATP    O
or    O
GTP    B-Purine114706749
by    O
the    O
direct    O
transfer    O
of    O
a    O
phosphoryl    O
(    O
PO3    O
)    O
group    O
to    O
ADP    O
or    O
GDP    B-Purine114706749
from    O
another    O
phosphorylated    O
compound    O
.    O

Their    O
work    O
revealed    O
that    O
the    O
addition    O
of    O
guanine    O
,    O
such    O
as    O
in    O
the    O
molecule    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
,    O
to    O
dopamine    O
binding    O
sites    O
could    O
increase    O
the    O
binding    O
affinity    O
of    O
the    O
D4    O
dopamine    O
receptor    O
while    O
decreasing    O
the    O
binding    O
affinity    O
of    O
the    O
D2    O
dopamine    O
receptor    O
.    O

Kinesins    O
are    O
structurally    O
related    O
to    O
G    O
proteins    O
,    O
which    O
hydrolyze    O
GTP    B-Purine114706749
instead    O
of    O
ATP    O
.    O

This    O
enables    O
EF    O
-    O
Tu    O
to    O
bind    O
to    O
a    O
new    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
molecule    O
,    O
release    O
EF    O
-    O
Ts    O
,    O
and    O
go    O
on    O
to    O
catalyze    O
another    O
aminoacyl    O
tRNA    O
addition    O
.    O

Aluminum    O
fluoride    O
complexes    O
are    O
used    O
to    O
study    O
the    O
mechanistic    O
aspects    O
of    O
phosphoryl    O
transfer    O
reactions    O
in    O
biology    O
,    O
which    O
are    O
of    O
fundamental    O
importance    O
to    O
cells    O
,    O
as    O
phosphoric    O
acid    O
anhydrides    O
such    O
as    O
ATP    O
and    O
GTP    B-Purine114706749
control    O
most    O
of    O
the    O
reactions    O
involved    O
in    O
metabolism    O
,    O
growth    O
and    O
differentiation    O
.    O

Guanosine    B-Purine114706749
triphosphate    I-Purine114706749
,    O
an    O
organic    O
chemical    O
and    O
energy    O
carrier    O

This    O
protein    O
recruits    O
a    O
small    O
GTPase    O
called    O
Sar1    O
(    O
think    O
of    O
Sar1    O
as    O
a    O
switch    O
,    O
it    O
is    O
active    O
when    O
bound    O
to    O
GTP    B-Purine114706749
and    O
inactive    O
when    O
it    O
hydrolyses    O
the    O
GTP    O
to    O
GDP    B-Purine114706749
)    O
.    O

Oxaloacetate    O
is    O
later    O
decarboxylated    O
and    O
phosphorylated    O
by    O
phosphoenolpyruvate    O
carboxykinase    O
and    O
becomes    O
2-phosphoenolpyruvate    O
using    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
(    O
GTP    O
)    O
as    O
phosphate    O
source    O
.    O

The    O
citric    O
acid    O
cycle    O
oxidizes    O
the    O
acetyl    O
-    O
CoA    O
to    O
carbon    O
dioxide    O
,    O
and    O
,    O
in    O
the    O
process    O
,    O
produces    O
reduced    O
cofactors    O
(    O
three    O
molecules    O
of    O
NADH    O
and    O
one    O
molecule    O
of    O
FADH2    O
)    O
that    O
are    O
a    O
source    O
of    O
electrons    O
for    O
the    O
"    O
electron    O
transport    O
chain    O
"    O
,    O
and    O
a    O
molecule    O
of    O
GTP    B-Purine114706749
(    O
that    O
is    O
readily    O
converted    O
to    O
an    O
ATP    O
)    O
.    O

Dock11    O
binds    O
and    O
activates    O
nucleotide    O
-    O
free    O
Cdc42    O
via    O
its    O
DHR2    O
domain    O
and    O
has    O
also    O
been    O
reported    O
to    O
mediate    O
positive    O
feedback    O
on    O
active    O
,    O
GTP    B-Purine114706749
-    O
bound    O
Cdc42    O
,    O
although    O
this    O
interaction    O
required    O
a    O
small    O
N    O
-    O
terminal    O
region    O
of    O
Dock11    O
in    O
addition    O
to    O
the    O
DHR2    O
domain    O
.    O

Furthermore    O
,    O
if    O
the    O
bound    O
AdoCbl    O
accrues    O
oxidative    O
damage    O
during    O
normal    O
functioning    O
,    O
"    O
MMAA    O
"    O
protein    O
fosters    O
exchange    O
of    O
the    O
damaged    O
cofactor    O
for    O
a    O
new    O
AdoCbl    O
via    O
a    O
GTP    B-Purine114706749
-    O
reliant    O
pathway    O
.    O

In    O
the    O
activated    O
NMBR    O
/    O
G    O
-    O
protein    O
complex    O
,    O
there    O
occurs    O
an    O
exchange    O
of    O
GTP    B-Purine114706749
for    O
GDP    B-Purine114706749
bound    O
to    O
G-α    O
subunit    O
.    O

The    O
main    O
function    O
of    O
the    O
SEC23A    O
protein    O
is    O
to    O
hydrolyze    O
or    O
break    O
down    O
a    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
(    O
GTP    O
)    O
molecule    O
bound    O
to    O
the    O
SAR1A    O
protein    O
at    O
the    O
start    O
of    O
the    O
COPII    O
pathway    O
.    O

GTP    B-Purine114706749
,    O
CTP    O
,    O
and    O
UTP    O
are    O
also    O
nucleotides    O
important    O
in    O
the    O
protein    O
synthesis    O
,    O
lipid    O
synthesis    O
,    O
and    O
carbohydrate    O
metabolism    O
,    O
respectively    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Purine114706749
and    O
beta    O
-    O
L    O
-    O
fucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
L    O
-    O
fucose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Purine114706749
and    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
glucose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GTP    B-Purine114706749
,    O
whereas    O
its    O
two    O
products    O
are    O
AMP    O
and    O
guanosine    O
3'-diphosphate    O
5'-triphosphate    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
GTP    B-Purine114706749
,    O
and    O
two    O
products    O
,    O
diphosphate    O
and    O
P1,P4-bis(5'-guanosyl    O
)    O
tetraphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Purine114706749
and    O
5-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Purine114706749
and    O
5-phosphonooxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Purine114706749
and    O
alpha    O
-    O
D    O
-    O
mannose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Purine114706749
and    O
(    O
5')ppPur    O
-    O
mRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
G(5')pppPur    O
-    O
mRNA    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Purine114706749
and    O
3-phospho    O
-    O
D    O
-    O
glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Purine114706749
and    O
3-phospho    O
-    O
D    O
-    O
glyceroyl    O
phosphate    O
.    O

Every    O
"    O
turn    O
"    O
of    O
the    O
citric    O
acid    O
cycle    O
produces    O
two    O
molecules    O
of    O
carbon    O
dioxide    O
,    O
one    O
equivalent    O
of    O
ATP    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
(    O
GTP    O
)    O
through    O
substrate    O
-    O
level    O
phosphorylation    O
catalyzed    O
by    O
succinyl    O
-    O
CoA    O
synthetase    O
,    O
three    O
molecules    O
of    O
NADH    O
,    O
and    O
one    O
equivalent    O
of    O
FADH2    O
.    O

GTP    B-Purine114706749
.    O

Arprinocid    B-Purine114706749
is    O
a    O
coccidiostat    O
(    O
or    O
more    O
likely    O
a    O
coccidiocide    O
,    O
i.e.    O
a    O
drug    O
killing    O
"    O
Coccidia    O
"    O
parasites    O
)    O
used    O
in    O
veterinary    O
medicine    O
.    O

Studies    O
have    O
shown    O
this    O
treatment    O
combined    O
with    O
valacyclovir    B-Purine114706749
to    O
be    O
effective    O
in    O
combating    O
HSV-1    O
and    O
eventually    O
returning    O
lymphocyte    O
counts    O
to    O
normal    O
.    O

Since    O
herpes    O
infections    O
often    O
lead    O
to    O
pleocytosis    O
,    O
aciclovir    B-Purine114706749
and    O
valacyclovir    B-Purine114706749
are    O
commonly    O
prescribed    O
.    O

Valaciclovir    B-Purine114706749
,    O
also    O
spelled    O
valacyclovir    B-Purine114706749
,    O
is    O
an    O
antiviral    O
drug    O
used    O
in    O
the    O
management    O
of    O
herpes    O
simplex    O
,    O
herpes    O
zoster    O
(    O
shingles    O
)    O
,    O
and    O
herpes    O
B.    O

Purine    B-Purine114706749
analogue    I-Purine114706749
of    O
guanine    O
:    O
Aciclovir    B-Purine114706749
,    O
Famciclovir    B-Purine114706749
,    O
Ganciclovir    B-Purine114706749
,    O
Penciclovir    O
,    O
Valaciclovir    B-Purine114706749
,    O
Valganciclovir    B-Purine114706749

9-Carboxymethoxymethylguanine    B-Purine114706749
(    O
CMMG    B-Purine114706749
)    O
is    O
a    O
compound    O
which    O
is    O
known    O
as    O
the    O
principal    O
metabolite    O
of    O
the    O
antiviral    O
drug    O
acyclovir    B-Purine114706749
(    O
and    O
its    O
prodrug    O
valacyclovir    B-Purine114706749
)    O
,    O
and    O
has    O
been    O
suggested    O
as    O
the    O
causative    O
agent    O
in    O
the    O
neuropsychiatric    O
side    O
effects    O
sometimes    O
associated    O
with    O
these    O
drugs    O
.    O

In    O
the    O
case    O
of    O
herpetic    O
uveitis    O
,    O
anti    O
-    O
viral    O
medications    O
,    O
such    O
as    O
valaciclovir    B-Purine114706749
or    O
aciclovir    B-Purine114706749
,    O
may    O
be    O
administered    O
to    O
treat    O
the    O
causative    O
viral    O
infection    O
.    O

Foods    O
high    O
in    O
the    O
purines    O
adenine    O
and    O
hypoxanthine    B-Purine114706749
may    O
be    O
more    O
potent    O
in    O
exacerbating    O
hyperuricemia    O
.    O

Specifically    O
,    O
it    O
catalyzes    O
the    O
conversion    O
of    O
inosine    O
to    O
hypoxanthine    B-Purine114706749
and    O
guanosine    O
to    O
guanine    O
(    O
both    O
guanine    O
and    O
hypoxanthine    O
will    O
be    O
made    O
into    O
xanthine    O
which    O
will    O
then    O
become    O
uric    O
acid    O
)    O
.    O

Examples    O
include    O
C    O
→    O
U    O
and    O
A    O
→    O
HX    O
(    O
hypoxanthine    B-Purine114706749
)    O
,    O
which    O
can    O
be    O
corrected    O
by    O
DNA    O
repair    O
mechanisms    O
;    O
and    O
5MeC    O
(    O
5-methylcytosine    O
)    O
→    O
T    O
,    O
which    O
is    O
less    O
likely    O
to    O
be    O
detected    O
as    O
a    O
mutation    O
because    O
thymine    O
is    O
a    O
normal    O
DNA    O
base    O
.    O

The    O
same    O
paper    O
suggested    O
that    O
FLT3L    O
release    O
was    O
caused    O
by    O
stimulation    O
of    O
mast    O
cells    O
with    O
uric    O
acid    O
,    O
produced    O
from    O
a    O
precursor    B-Purine114706749
secreted    O
by    O
the    O
plasmodium    O
parasite    O
.    O
.    O

It    O
differs    O
from    O
other    O
nucleoside    O
analogues    O
,    O
because    O
it    O
does    O
not    O
have    O
any    O
of    O
the    O
regular    O
bases    O
,    O
instead    O
it    O
has    O
hypoxanthine    B-Purine114706749
attached    O
to    O
the    O
sugar    O
ring    O
.    O

Hypoxanthine    B-Purine114706749
and    O
xanthine    O
are    O
two    O
of    O
the    O
many    O
bases    O
created    O
through    O
mutagen    O
presence    O
,    O
both    O
of    O
them    O
through    O
deamination    O
(    O
replacement    O
of    O
the    O
amine    O
-    O
group    O
with    O
a    O
carbonyl    O
-    O
group    O
)    O
.    O

Hypoxanthine    B-Purine114706749

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
dAMP    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
dADP    B-Purine114706749
.    O

Aciclovir    B-Purine114706749

Vidarabine    O
is    O
more    O
toxic    O
and    O
less    O
metabolically    O
stable    O
than    O
many    O
of    O
the    O
other    O
current    O
antivirals    O
such    O
as    O
acyclovir    B-Purine114706749
and    O
ganciclovir    B-Purine114706749
.    O

Many    O
of    O
the    O
previous    O
uses    O
of    O
vidarabine    O
have    O
been    O
superseded    O
by    O
acyclovir    B-Purine114706749
,    O
due    O
to    O
the    O
hospitalisation    O
required    O
for    O
intra    O
venous    O
dosing    O
,    O
and    O
acyclovir    O
has    O
a    O
higher    O
selectivity    O
,    O
lower    O
inhibitory    O
concentration    O
and    O
higher    O
potency    O
.    O

Aciclovir    B-Purine114706749
(    O
ACV    B-Purine114706749
)    O
,    O
also    O
known    O
as    O
acyclovir    B-Purine114706749
,    O
is    O
an    O
antiviral    O
medication    O
.    O

It    O
is    O
a    O
prodrug    O
,    O
being    O
converted    O
to    O
aciclovir    B-Purine114706749
.    O

Common    O
adverse    O
drug    O
reactions    O
(    O
≥1%    O
of    O
patients    O
)    O
associated    O
with    O
valaciclovir    O
therapy    O
are    O
the    O
same    O
as    O
for    O
aciclovir    B-Purine114706749
,    O
its    O
active    O
metabolite    O
,    O
and    O
include    O
:    O
nausea    O
,    O
vomiting    O
,    O
diarrhea    O
and    O
headache    O
.    O

Valaciclovir    O
is    O
a    O
prodrug    O
,    O
an    O
esterified    O
version    O
of    O
aciclovir    B-Purine114706749
that    O
has    O
greater    O
oral    O
bioavailability    O
(    O
about    O
55%    O
)    O
than    O
aciclovir    O
(    O
10–20%    O
)    O
.    O

It    O
is    O
converted    O
by    O
esterases    O
to    O
the    O
active    O
drug    O
aciclovir    B-Purine114706749
,    O
as    O
well    O
as    O
the    O
amino    O
acid    O
valine    O
,    O
via    O
hepatic    O
first    O
-    O
pass    O
metabolism    O
.    O

Aciclovir    B-Purine114706749
is    O
selectively    O
converted    O
into    O
a    O
monophosphate    O
form    O
by    O
viral    O
thymidine    O
kinase    O
,    O
which    O
is    O
far    O
more    O
effective    O
(    O
3000    O
times    O
)    O
in    O
phosphorylation    O
of    O
aciclovir    B-Purine114706749
than    O
cellular    O
thymidine    O
kinase    O
.    O

Purine    B-Purine114706749
analogue    I-Purine114706749
of    O
guanine    O
:    O
Aciclovir    B-Purine114706749
,    O
Famciclovir    B-Purine114706749
,    O
Ganciclovir    B-Purine114706749
,    O
Penciclovir    O
,    O
Valaciclovir    B-Purine114706749
,    O
Valganciclovir    B-Purine114706749

9-Carboxymethoxymethylguanine    B-Purine114706749
(    O
CMMG    B-Purine114706749
)    O
is    O
a    O
compound    O
which    O
is    O
known    O
as    O
the    O
principal    O
metabolite    O
of    O
the    O
antiviral    O
drug    O
acyclovir    B-Purine114706749
(    O
and    O
its    O
prodrug    O
valacyclovir    B-Purine114706749
)    O
,    O
and    O
has    O
been    O
suggested    O
as    O
the    O
causative    O
agent    O
in    O
the    O
neuropsychiatric    O
side    O
effects    O
sometimes    O
associated    O
with    O
these    O
drugs    O
.    O

As    O
a    O
graduate    O
student    O
,    O
Vince    O
’s    O
research    O
on    O
the    O
design    O
of    O
acyclonucleosides    O
,    O
with    O
Howard    O
J.    O
Schaeffer    O
at    O
SUNY    O
Buffalo    O
became    O
an    O
integral    O
part    O
of    O
the    O
discovery    O
of    O
anti    O
-    O
viral    O
drug    O
acyclovir    B-Purine114706749
.    O

Later    O
,    O
Prof    O
Schaeffer    O
continued    O
the    O
development    O
of    O
acyclovir    B-Purine114706749
at    O
Burroughs    O
Welcome    O
&    O
Company    O
,    O
with    O
pharmacologist    O
Gertrude    O
B.    O
Elion    O
who    O
was    O
awarded    O
the    O
1988    O
Nobel    O
Prize    O
in    O
Medicine    O
,    O
in    O
part    O
,    O
for    O
the    O
development    O
of    O
acyclovir    B-Purine114706749
.    O

He    O
also    O
starred    O
in    O
a    O
TV    O
advert    O
for    O
Zovirax    B-Purine114706749
cold    O
sore    O
cream    O
.    O

In    O
the    O
case    O
of    O
herpetic    O
uveitis    O
,    O
anti    O
-    O
viral    O
medications    O
,    O
such    O
as    O
valaciclovir    B-Purine114706749
or    O
aciclovir    B-Purine114706749
,    O
may    O
be    O
administered    O
to    O
treat    O
the    O
causative    O
viral    O
infection    O
.    O

Entecavir    B-Purine114706749

Entecavir    B-Purine114706749
,    O
also    O
called    O
ETV    O
,    O
is    O
a    O
guanosine    O
analog    O
used    O
for    O
hepatitis    O
B    O
under    O
the    O
trade    O
name    O
Baraclude    O
.    O

Guanosine    O
analogues    O
:    O
abacavir    B-Purine114706749
(    O
ABC    O
)    O
and    O
entecavir    B-Purine114706749
(    O
ETV    O
)    O

The    O
cytokinin    O
zeatin    B-Purine114706749
is    O
named    O
after    O
the    O
genus    O
of    O
corn    O
,    O
"    O
Zea    O
"    O
,    O
in    O
which    O
it    O
was    O
discovered    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
O    O
-    O
acetyl    O
-    O
L    O
-    O
serine    O
and    O
zeatin    B-Purine114706749
,    O
whereas    O
its    O
two    O
products    O
are    O
lupinate    O
and    O
acetate    O
.    O

RelA    O
converts    O
GTP    B-Purine114706749
and    O
ATP    O
into    O
pppGpp    B-Purine114706749
by    O
adding    O
the    O
pyrophosphate    O
from    O
ATP    O
onto    O
the    O
3    O
'    O
carbon    O
of    O
the    O
ribose    O
in    O
GTP    O
,    O
releasing    O
AMP    O
.    O

pppGpp    O
is    O
converted    O
to    O
ppGpp    B-Purine114706749
by    O
the    O
"    O
gpp    O
"    O
gene    O
product    O
,    O
releasing    O
Pi    O
.    O

2006    O
:    O
Bertilo    O
Wennergren    O
(    O
b.    O
1956    O
in    O
Sweden    O
)    O
for    O
his    O
masterwork    O
,    O
the    O
"    O
Plena    B-Purine114706749
Manlibro    I-Purine114706749
de    I-Purine114706749
Esperanta    I-Purine114706749
Gramatiko    I-Purine114706749
"    O
,    O
an    O
exhaustive    O
treatment    O
of    O
Esperanto    O
grammar    O

Later    O
that    O
year    O
Hepsera    O
(    O
adefovir    B-Purine114706749
)    O
was    O
approved    O
for    O
the    O
treatment    O
of    O
chronic    O
hepatitis    O
B    O
,    O
and    O
Emtriva    O
(    O
emtricitabine    O
)    O
for    O
the    O
treatment    O
of    O
HIV    O
.    O

Adefovir    B-Purine114706749
,    O
also    O
known    O
as    O
ADV    O
or    O
bis    O
-    O
POM    O
PMPA    O
,    O
has    O
trade    O
names    O
Preveon    O
and    O
Hepsera    B-Purine114706749
.    O

Adenosine    O
analogues    O
:    O
didanosine    O
(    O
ddI    O
)    O
,    O
tenofovir    B-Purine114706749
(    O
TDF    O
)    O
,    O
and    O
adefovir    B-Purine114706749
(    O
ADV    O
)    O

Nelarabine    B-Purine114706749
for    O
cancer    O
treatment    O
.    O

File    O
:    O
Nelarabine    O
Nelarabine    B-Purine114706749

For    O
example    O
,    O
enzyme    O
deoxyribonucleoside    O
triphosphate    O
pyrophosphatase    O
,    O
encoded    O
by    O
YJR069C    O
in    O
"    O
S.    O
cerevisiae    O
"    O
and    O
exhibiting    O
(    O
d)ITPase    O
and    O
(    O
d)XTPase    O
activities    O
,    O
hydrolyses    O
ITP    O
,    O
dITP    O
,    O
XTP    B-Purine114706749
and    O
dXTP    O
releasing    O
pyrophosphate    O
and    O
IMP    B-Purine114706749
,    O
dIMP    B-Purine114706749
,    O
XMP    B-Purine114706749
and    O
dXMP    O
,    O
respectively    O
.    O

Benzocaine    O
was    O
used    O
in    O
synthesis    O
of    O
leteprinim    B-Purine114706749
.    O

In    O
2004    O
,    O
Gilead    O
launched    O
Truvada    O
,    O
a    O
fixed    O
-    O
dose    O
combination    O
of    O
tenofovir    B-Purine114706749
and    O
emtricitabine    O
.    O

In    O
July    O
2006    O
,    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
approved    O
Atripla    O
,    O
a    O
once    O
a    O
day    O
single    O
tablet    O
regimen    O
for    O
HIV    O
,    O
combining    O
Sustiva    O
(    O
efavirenz    O
)    O
,    O
a    O
Bristol    O
-    O
Myers    O
Squibb    O
product    O
,    O
and    O
Truvada    O
(    O
emtricitabine    O
and    O
tenofovir    B-Purine114706749
disoproxil    I-Purine114706749
)    O
,    O
a    O
Gilead    O
product    O
.    O

Tenofovir    B-Purine114706749
,    O
also    O
known    O
as    O
TDF    O
is    O
a    O
so    O
-    O
called    O
'    O
prodrug    O
'    O
with    O
the    O
active    O
compound    O
deactivated    O
by    O
a    O
molecular    O
side    O
chain    O
that    O
dissolves    O
in    O
the    O
human    O
body    O
allowing    O
a    O
low    O
dose    O
of    O
tenofovir    O
to    O
reach    O
the    O
site    O
of    O
desired    O
activity    O
.    O

Adenosine    O
analogues    O
:    O
didanosine    O
(    O
ddI    O
)    O
,    O
tenofovir    B-Purine114706749
(    O
TDF    O
)    O
,    O
and    O
adefovir    B-Purine114706749
(    O
ADV    O
)    O

Zidovudine    O
(    O
AZT    O
)    O
or    O
tenofovir    B-Purine114706749
(    O
TDF    O
)    O
are    O
recommended    O
as    O
less    O
toxic    O
and    O
equally    O
effective    O
alternatives    O
.    O
"    O

The    O
drug    O
tenofovir    B-Purine114706749
has    O
had    O
its    O
efficacy    O
and    O
toxicology    O
evaluated    O
in    O
macaques    O
and    O
found    O
long    O
-    O
term    O
/    O
high    O
-    O
dose    O
treatments    O
had    O
adverse    O
effects    O
not    O
found    O
using    O
short    O
-    O
term    O
/    O
high    O
-    O
dose    O
treatment    O
followed    O
by    O
long    O
-    O
term    O
/    O
low    O
-    O
dose    O
treatment    O
.    O

iPrEx    O
(    O
from    O
,    O
"    O
pre    O
-    O
exposure    O
prophylaxis    O
initiative    O
"    O
)    O
was    O
a    O
phase    O
III    O
clinical    O
trial    O
to    O
determine    O
whether    O
the    O
antiretroviral    O
medication    O
emtricitabine    O
/    O
tenofovir    O
(    O
as    O
tenofovir    B-Purine114706749
disoproxil    I-Purine114706749
fumarate    I-Purine114706749
)    O
could    O
safely    O
and    O
effectively    O
prevent    O
HIV    O
acquisition    O
through    O
sex    O
in    O
men    O
who    O
have    O
sex    O
with    O
men    O
and    O
transgender    O
women    O
.    O

Elvitegravir    O
,    O
emtricitabine    O
and    O
tenofovir    B-Purine114706749
directly    O
suppress    O
viral    O
reproduction    O
.    O

Taking    O
the    O
AIDS    O
drug    O
tenofovir    B-Purine114706749
greatly    O
reduces    O
the    O
risk    O
of    O
HIV    O
infection    O
among    O
intravenous    O
drug    O
users    O
,    O
according    O
to    O
a    O
new    O
study    O
.    O

Physiological    O
agonist    O
:    O
Cyclic    B-Purine114706749
ADP-ribose    I-Purine114706749
can    O
act    O
as    O
a    O
physiological    O
gating    O
agent    O
.    O

NAD+    O
is    O
converted    O
into    O
cyclic    B-Purine114706749
ADP    I-Purine114706749
ribose    I-Purine114706749
(    O
cADPR    O
)    O
,    O
a    O
second    O
messenger    O
which    O
interacts    O
with    O
ryanodine    O
receptors    O
(    O
RyR    O
)    O
on    O
the    O
surface    O
of    O
the    O
rough    O
endoplasmic    O
reticulum    O
.    O

Calcium    B-Purine114706749
inosinate    I-Purine114706749
,    O
a    O
food    O
additive    O

STING    O
has    O
been    O
shown    O
to    O
bind    O
directly    O
to    O
cyclic    B-Purine114706749
di-GMP    I-Purine114706749
,    O
and    O
this    O
recognition    O
leads    O
to    O
the    O
production    O
of    O
cytokines    O
,    O
such    O
as    O
type    O
I    O
interferon    O
,    O
that    O
are    O
essential    O
for    O
successful    O
pathogen    O
elimination    O
.    O

Some    O
motility    O
regulatory    O
linkages    O
that    O
H    O
-    O
NS    O
influences    O
include    O
the    O
messenger    O
molecule    O
Cyclic    B-Purine114706749
di-GMP    I-Purine114706749
,    O
the    O
bio    O
-    O
film    O
regulatory    O
protein    O
CsgD    O
,    O
and    O
the    O
sigma    O
factors    O
,    O
σ(S    O
)    O
and    O
σ(F    O
)    O
.    O

During    O
DNA    O
replication    O
of    O
the    O
"    O
Saccharomyces    O
cerevisiae    O
"    O
chromosome    O
,    O
the    O
oxidative    O
DNA    O
damage    O
8-oxoguanine    B-Purine114706749
triggers    O
a    O
switch    O
to    O
translesion    O
synthesis    O
by    O
DNA    O
polymerase    O
eta    O
.    O

Ionizing    O
radiation    O
and    O
reactive    O
oxygen    O
species    O
often    O
oxidize    O
guanine    O
to    O
produce    O
8-oxoguanine    B-Purine114706749
.    O

The    O
oxidative    O
damage    O
is    O
caused    O
by    O
modification    O
of    O
DNA    O
nucleobases    O
,    O
in    O
particular    O
8-oxoguanine    B-Purine114706749
(    O
8-OHdG    O
)    O
which    O
leads    O
to    O
G    O
:    O
C    O
to    O
T    O
:    O
A    O
mutations    O
.    O

There    O
are    O
two    O
types    O
of    O
cytokinins    O
:    O
adenine    O
-    O
type    O
cytokinins    O
represented    O
by    O
kinetin    B-Purine114706749
,    O
zeatin    B-Purine114706749
,    O
and    O
6-benzylaminopurine    B-Purine114706749
,    O
and    O
phenylurea    O
-    O
type    O
cytokinins    O
like    O
diphenylurea    O
and    O
thidiazuron    O
(    O
TDZ    O
)    O
.    O

Roscovitine    B-Purine114706749
is    O
an    O
inhibitor    O
of    O
cyclin    O
-    O
dependent    O
kinase    O
.    O

The    O
early    O
days    O
of    O
research    O
in    O
this    O
field    O
yielded    O
discoveries    O
about    O
the    O
potential    O
of    O
certain    O
chemicals    O
such    O
as    O
bisulfite    O
and    O
aminopurine    B-Purine114706749
to    O
change    O
certain    O
bases    O
in    O
a    O
gene    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
xanthosine    B-Purine114706749
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
7-methylxanthosine    O
.    O

GMP    O
is    O
formed    O
by    O
the    O
inosinate    O
oxidation    O
to    O
xanthylate    B-Purine114706749
(    O
XMP    O
)    O
,    O
and    O
afterwards    O
adds    O
an    O
amino    O
group    O
on    O
carbon    O
2    O
.    O

Xanthosine    B-Purine114706749
monophosphate    I-Purine114706749

Xanthosine    B-Purine114706749
monophosphate    I-Purine114706749

Vidarabine    O
is    O
more    O
toxic    O
and    O
less    O
metabolically    O
stable    O
than    O
many    O
of    O
the    O
other    O
current    O
antivirals    O
such    O
as    O
acyclovir    B-Purine114706749
and    O
ganciclovir    B-Purine114706749
.    O

Foscarnet    O
,    O
ganciclovir    B-Purine114706749
,    O
tenofovir    B-Purine114706749
,    O
adefovir    B-Purine114706749
:    O
Risk    O
of    O
hematological    O
and    O
renal    O
side    O
effects    O
of    O
amphotericin    O
B    O
are    O
increased    O

Purine    B-Purine114706749
analogue    I-Purine114706749
of    O
guanine    O
:    O
Aciclovir    B-Purine114706749
,    O
Famciclovir    B-Purine114706749
,    O
Ganciclovir    B-Purine114706749
,    O
Penciclovir    O
,    O
Valaciclovir    B-Purine114706749
,    O
Valganciclovir    B-Purine114706749

In    O
terms    O
of    O
the    O
treatment    O
of    O
cytomegalovirus    O
retinitis    O
,    O
oral    O
valganciclovir    B-Purine114706749
,    O
intravenous    O
ganciclovir    B-Purine114706749
,    O
IV    O
foscarnet    O
,    O
and    O
IV    O
cidofovir    O
are    O
all    O
efficient    O
in    O
the    O
treatment    O
of    O
this    O
condition    O
.    O

The    O
"    O
Thermoanaerobacter    O
tengcongensis    O
"    O
sequence    O
AE013027    O
overlaps    O
with    O
that    O
of    O
purine    B-Purine114706749
riboswitch    I-Purine114706749
suggesting    O
that    O
the    O
two    O
riboswitches    O
may    O
work    O
in    O
conjunction    O
to    O
regulate    O
the    O
upstream    O
gene    O
which    O
codes    O
for    O
TTE0584    O
(    O
Q8RC62    O
)    O
,    O
a    O
member    O
of    O
the    O
permease    O
family    O
.    O

9-Carboxymethoxymethylguanine    B-Purine114706749
(    O
CMMG    B-Purine114706749
)    O
is    O
a    O
compound    O
which    O
is    O
known    O
as    O
the    O
principal    O
metabolite    O
of    O
the    O
antiviral    O
drug    O
acyclovir    B-Purine114706749
(    O
and    O
its    O
prodrug    O
valacyclovir    B-Purine114706749
)    O
,    O
and    O
has    O
been    O
suggested    O
as    O
the    O
causative    O
agent    O
in    O
the    O
neuropsychiatric    O
side    O
effects    O
sometimes    O
associated    O
with    O
these    O
drugs    O
.    O

CP-532,903    B-Purine114706749

Two    O
formylation    O
reactions    O
are    O
required    O
in    O
the    O
eleven    O
step    O
de    O
novo    O
synthesis    O
of    O
inosine    B-Purine114706749
monophosphate    I-Purine114706749
(IMP)    I-Purine114706749
,    O
the    O
precursor    O
of    O
the    O
purine    O
ribonucleotides    O
AMP    O
and    O
GMP    O
.    O

Inosinic    B-Purine114706749
acid    I-Purine114706749
or    O
inosine    B-Purine114706749
monophosphate    I-Purine114706749
(    O
IMP    B-Purine114706749
)    O
is    O
a    O
nucleoside    O
monophosphate    O
.    O

The    O
umami    O
taste    O
is    O
most    O
frequently    O
associated    O
with    O
the    O
food    O
additive    O
monosodium    O
glutamate    O
(    O
MSG    O
)    O
and    O
can    O
be    O
enhanced    O
through    O
the    O
binding    O
of    O
inosine    B-Purine114706749
monophosphate    I-Purine114706749
(    O
IMP    O
)    O
and    O
guanosine    B-Purine114706749
monophosphate    I-Purine114706749
(    O
GMP    O
)    O
molecules    O
.    O

Poly    O
I    O
:    O
C    O
is    O
a    O
mismatched    O
double    O
-    O
stranded    O
RNA    O
with    O
one    O
strand    O
being    O
a    O
polymer    O
of    O
inosinic    B-Purine114706749
acid    I-Purine114706749
,    O
the    O
other    O
a    O
polymer    O
of    O
cytidylic    O
acid    O
.    O

It    O
is    O
produced    O
by    O
combining    O
the    O
sodium    O
salts    O
of    O
the    O
natural    O
compounds    O
guanylic    B-Purine114706749
acid    I-Purine114706749
(    O
E626    O
)    O
and    O
inosinic    B-Purine114706749
acid    I-Purine114706749
(    O
E630    O
)    O
.    O

Disodium    B-Purine114706749
inosinate    I-Purine114706749
(    O
E631    B-Purine114706749
)    O
is    O
the    O
disodium    O
salt    O
of    O
inosinic    B-Purine114706749
acid    I-Purine114706749
with    O
the    O
chemical    O
formula    O
C10H11N4Na2O8P.    O
It    O
is    O
used    O
as    O
a    O
food    O
additive    O
and    O
often    O
found    O
in    O
instant    O
noodles    O
,    O
potato    O
chips    O
,    O
and    O
a    O
variety    O
of    O
other    O
snacks    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
inosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
IMP    B-Purine114706749
.    O

Another    O
synthetic    O
drug    O
specific    O
to    O
the    O
adenosine    O
A2A    O
receptor    O
subtype    O
is    O
CGS-21680    B-Purine114706749
that    O
has    O
been    O
shown    O
to    O
cause    O
apneas    O
in    O
14-    O
to    O
21-day    O
-    O
old    O
rat    O
pups    O
"    O
in    O
vivo    O
"    O
.    O

Deoxyguanosine    B-Purine114706749
diphosphate    I-Purine114706749

It    O
is    O
similar    O
to    O
"N"6-cyclopentyladenosine    B-Purine114706749
.    O

Purinones    B-Purine114706749
are    O
derivatives    O
of    O
purine    O
which    O
have    O
a    O
substituted    O
keto    O
group    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
O    O
-    O
demethylpuromycin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
puromycin    B-Purine114706749
.    O

The    O
process    O
results    O
in    O
translated    O
peptides    O
or    O
proteins    O
that    O
are    O
associated    O
with    O
their    O
mRNA    O
progenitor    O
via    O
a    O
puromycin    B-Purine114706749
linkage    O
.    O

Puromycin    B-Purine114706749
is    O
an    O
analogue    O
of    O
the    O
3’    O
end    O
of    O
a    O
tyrosyl    O
-    O
tRNA    O
with    O
a    O
part    O
of    O
its    O
structure    O
mimics    O
a    O
molecule    O
of    O
adenosine    O
,    O
and    O
the    O
other    O
part    O
mimics    O
a    O
molecule    O
of    O
tyrosine    O
.    O

The    O
interconversion    O
of    O
AMP    O
and    O
IMP    O
occurs    O
as    O
part    O
of    O
the    O
purine    B-Purine114706749
nucleotide    I-Purine114706749
cycle    I-Purine114706749
.    O

Several    O
groups    O
are    O
working    O
on    O
alternative    O
"    O
extra    O
"    O
base    O
pairs    O
to    O
extend    O
the    O
genetic    O
code    O
,    O
such    O
as    O
isoguanine    B-Purine114706749
and    O
isocytosine    O
or    O
the    O
fluorescent    O
2-amino-6-(2-thienyl)purine    O
and    O
pyrrole-2-carbaldehyde    O
.    O

Disodium    O
guanylate    O
,    O
also    O
known    O
as    O
sodium    O
5'-guanylate    O
and    O
disodium    O
5'-guanylate    O
,    O
is    O
a    O
natural    O
sodium    O
salt    O
of    O
the    O
flavor    O
enhancing    O
nucleotide    O
guanosine    B-Purine114706749
monophosphate    I-Purine114706749
(    O
GMP    O
)    O
.    O

It    O
is    O
produced    O
by    O
combining    O
the    O
sodium    O
salts    O
of    O
the    O
natural    O
compounds    O
guanylic    B-Purine114706749
acid    I-Purine114706749
(    O
E626    O
)    O
and    O
inosinic    B-Purine114706749
acid    I-Purine114706749
(    O
E630    O
)    O
.    O

It    O
reversibly    O
inhibits    O
inosine    O
monophosphate    O
dehydrogenase    O
,    O
the    O
enzyme    O
that    O
controls    O
the    O
rate    O
of    O
synthesis    O
of    O
guanine    B-Purine114706749
monophosphate    I-Purine114706749
in    O
the    O
"    O
de    O
novo    O
"    O
pathway    O
of    O
purine    O
synthesis    O
used    O
in    O
the    O
proliferation    O
of    O
B    O
and    O
T    O
lymphocytes    O
.    O

Guanosine    B-Purine114706749
monophosphate    I-Purine114706749

:    O
ATP    O
+    O
GMP    B-Purine114706749
ADP    O
+    O
GDP    B-Purine114706749

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GMP    B-Purine114706749
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
GDP    B-Purine114706749
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    O
-    O
mannose    O
and    O
(    O
phosphomannan)n    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GMP    B-Purine114706749
and    O
(    O
phosphomannan)n+1    O
.    O

Thioinosinic    B-Purine114706749
acid    I-Purine114706749
(    O
or    O
thioinosine    B-Purine114706749
monophosphate    I-Purine114706749
,    O
TIMP    B-Purine114706749
)    O
is    O
an    O
intermediate    O
metabolite    O
of    O
azathioprine    O
,    O
an    O
immunosuppressive    O
drug    O
.    O

lodenosine    B-Purine114706749
(    O
INN    O
)    O

Otenabant    B-Purine114706749

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dGTP    B-Purine114706749
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
deoxyguanosine    O
and    O
triphosphate    O
.    O

To    O
measure    O
ADA2    O
,    O
erythro-9-(2-hydroxy-3-nonyl)    B-Purine114706749
adenine    I-Purine114706749
(    O
EHNA    O
)    O
is    O
added    O
prior    O
to    O
incubation    O
so    O
as    O
to    O
inhibit    O
the    O
enzymatic    O
activity    O
of    O
ADA1    O
.    O

Abacavir    B-Purine114706749
(    O
ABC    B-Purine114706749
)    O
is    O
a    O
medication    O
used    O
to    O
prevent    O
and    O
treat    O
HIV    O
/    O
AIDS    O
.    O

This    O
class    O
of    O
medicinal    O
agents    O
included    O
the    O
drug    O
abacavir    B-Purine114706749
.    O

Abacavir    O
was    O
commercialized    O
by    O
GlaxoSmithKline    O
as    O
Ziagen    B-Purine114706749
for    O
the    O
treatment    O
of    O
AIDS    O
.    O

His    O
synthesis    O
of    O
abacavir    B-Purine114706749
made    O
use    O
of    O
a    O
bicyclic    O
γ-lactam    O
,    O
2-azabicyclo[2.2.1]hept-5-en-3-one    O
,    O
as    O
a    O
chemical    O
precursor    O
.    O

Abacavir    B-Purine114706749
,    O
an    O
antiretroviral    O
drug    O
used    O
to    O
treat    O
HIV    O
/    O
AIDS    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
N7-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
2'-O    O
-    O
methylguanosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
containing    O
uridine    O
at    O
position    O
54    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
ribothymidine    O
at    O
position    O
54    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
L    O
-    O
tryptophan    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
L-2-methyltryptophan    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tyramine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
N    O
-    O
methyltyramine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
vitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
7-O    O
-    O
methylvitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
xanthotoxol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
O    O
-    O
methylxanthotoxol    O
.    O

A    O
SAM    B-Purine114706749
-    O
dependent    O
"    O
N    O
"-    O
methylation    O
of    O
putrescine    O
gives    O
the    O
"    O
N    O
"-    O
methylputrescine    O
product    O
,    O
which    O
then    O
undergoes    O
oxidative    O
deamination    O
by    O
the    O
action    O
of    O
diamine    O
oxidase    O
to    O
yield    O
the    O
aminoaldehyde    O
.    O

S-Adenosyl    B-Purine114706749
methionine    I-Purine114706749
(    O
SAM    O
)    O
can    O
act    O
as    O
a    O
catalyst    O
for    O
the    O
transfer    O
of    O
methyl    O
group    O
from    O
the    O
sulfonium    O
compound    O
to    O
nucleophile    O
.    O

Vitamin    O
B12    O
,    O
or    O
cobalamin    O
,    O
acts    O
as    O
a    O
cofactor    O
for    O
the    O
enzyme    O
methionine    O
synthase    O
(    O
which    O
forms    O
part    O
of    O
the    O
S-adenosylmethionine    B-Purine114706749
(    O
SAMe    O
)    O
biosynthesis    O
and    O
regeneration    O
cycle    O
)    O
.    O

S-Adenosyl    B-Purine114706749
methionine    I-Purine114706749
(    O
SAMe    O
)    O
is    O
available    O
as    O
a    O
prescription    O
antidepressant    O
in    O
Europe    O
and    O
an    O
over    O
-    O
the    O
-    O
counter    O
dietary    O
supplement    O
in    O
the    O
US    O
.    O

One    O
review    O
claimed    O
benefit    O
for    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
in    O
disease    O
models    O
.    O

The    O
alkaloid    O
berberine    O
has    O
a    O
tetracyclic    O
skeleton    O
derived    O
from    O
a    O
benzyltetrahydroisoquinoline    O
system    O
with    O
the    O
incorporation    O
of    O
an    O
extra    O
carbon    O
atom    O
provided    O
by    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
(    O
SAM    O
)    O
via    O
an    O
"    O
N    O
"-    O
methyl    O
group    O
.    O

After    O
oxidation    O
and    O
methylation    O
by    O
SAM    B-Purine114706749
,    O
(    O
"    O
S")-reticuline    O
4    O
is    O
formed    O
.    O

Histamine    O
N    O
-    O
methyltransferase    O
catalyzes    O
the    O
methylation    O
of    O
histamine    O
in    O
the    O
presence    O
of    O
S-adenosylmethionine    B-Purine114706749
(    O
SAM    O
)    O
forming    O
N    O
-    O
methylhistamine    O
.    O

This    O
gene    O
encodes    O
the    O
first    O
enzyme    O
which    O
is    O
found    O
in    O
the    O
cytosol    O
and    O
uses    O
S-adenosyl-L-methionine    B-Purine114706749
as    O
the    O
methyl    O
donor    O
.    O

In    O
the    O
first    O
step    O
of    O
the    O
biosynthesis    O
these    O
two    O
amino    O
acids    O
are    O
combined    O
by    O
the    O
enzyme    O
arginine    O
:    O
glycine    O
amidinotransferase    O
(    O
AGAT    O
,    O
EC:2.1.4.1    O
)    O
to    O
form    O
guanidinoacetate    O
,    O
which    O
is    O
then    O
methylated    O
by    O
guanidinoacetate    O
N    O
-    O
methyltransferase    O
(    O
GAMT    O
,    O
EC:2.1.1.2    O
)    O
,    O
using    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
as    O
the    O
methyl    O
donor    O
.    O

The    O
pathway    O
for    O
the    O
synthesis    O
of    O
creatineArg    O
-    O
Arginine    O
;    O
GATM    O
-    O
Glycine    O
amidinotransferase    O
;    O
GAMT    O
-    O
Guanidinoacetate    O
N    O
-    O
methyltransferase    O
;    O
Gly    O
-    O
Glycine    O
;    O
Met    O
-    O
Methionine    O
;    O
SAH    O
-    O
S-adenosyl    B-Purine114706749
homocysteine    I-Purine114706749
;    O
SAM    O
-    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
.    O

Diphthamide    O
is    O
biosynthesized    O
from    O
histidine    O
and    O
"S"-adenosyl    B-Purine114706749
methionine    I-Purine114706749
.    O

Adequate    O
methionine    O
(    O
which    O
,    O
like    O
folate    O
,    O
must    O
otherwise    O
be    O
obtained    O
in    O
the    O
diet    O
,    O
if    O
it    O
is    O
not    O
regenerated    O
from    O
homocysteine    O
by    O
a    O
B12    O
dependent    O
reaction    O
)    O
is    O
needed    O
to    O
make    O
"S"-adenosyl    B-Purine114706749
methionine    I-Purine114706749
(    O
SAMe    O
)    O
,    O
which    O
is    O
in    O
turn    O
necessary    O
for    O
methylation    O
of    O
myelin    O
sheath    O
phospholipids    O
.    O

Vitamin    O
methylcobalamin    O
and    O
5-methyltetrahydrofolate    O
are    O
needed    O
by    O
Methionine    O
synthase    O
in    O
the    O
Methionine    O
cycle    O
to    O
transfer    O
a    O
methyl    O
group    O
from    O
5-methyltetrahydrofolate    O
to    O
homocysteine    O
,    O
thereby    O
generating    O
tetrahydrofolate    O
(    O
THF    O
)    O
and    O
methionine    O
,    O
which    O
is    O
used    O
to    O
make    O
SAMe    B-Purine114706749
.    O

SAMe    B-Purine114706749
is    O
the    O
universal    O
methyl    O
donor    O
and    O
is    O
used    O
for    O
DNA    O
methylation    O
and    O
to    O
make    O
phospholipid    O
membranes    O
,    O
choline    O
,    O
sphingomyelin    O
and    O
acetylcholine    O
and    O
other    O
neurotransmitters    O
.    O

PFL    O
activase    O
is    O
part    O
of    O
the    O
radical    O
SAM    O
(    O
S-adenosylmethionine    B-Purine114706749
)    O
superfamily    O
.    O

The    O
5    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
,    O
malonyl    O
-    O
CoA    O
,    O
NADPH    O
,    O
H+    O
,    O
and    O
S-adenosyl-L-methionine    B-Purine114706749
,    O
whereas    O
its    O
6    O
products    O
are    O
dihydromonacolin    O
L    O
,    O
CoA    O
,    O
CO2    O
,    O
NADP+    O
,    O
S-adenosyl-L-homocysteine    B-Purine114706749
,    O
and    O
H2O.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
S-adenosyl-L-methionine    B-Purine114706749
,    O
and    O
two    O
products    O
,    O
5'-methylthioadenosine    O
and    O
2-aminobutan-4-olide    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-methionine    B-Purine114706749
and    O
N6-(Delta2-isopentenyl)-adenine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
5'-methylthioadenosine    O
and    O
discadenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-methionine    B-Purine114706749
and    O
nocardicin    O
E    O
,    O
whereas    O
its    O
two    O
products    O
are    O
5'-methylthioadenosine    O
and    O
isonocardicin    O
A.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
S-adenosyl-L-methionine    B-Purine114706749
,    O
and    O
two    O
products    O
,    O
S    O
-    O
methyl-5'-thioadenosine    O
and    O
nicotianamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-methionine    B-Purine114706749
and    O
tRNA    O
uridine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
5'-methylthioadenosine    O
and    O
tRNA    O
3-(3-amino-3-carboxypropyl)-uridine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-methionine    B-Purine114706749
and    O
8-amino-7-oxononanoate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosyl-4-methylthio-2-oxobutanoate    O
and    O
7,8-diaminononanoate    O
.    O

Although    O
the    O
mechanism    O
of    O
methylation    O
of    O
arsenic    O
in    O
humans    O
has    O
not    O
been    O
elucidated    O
,    O
the    O
source    O
of    O
methyl    O
is    O
methionine    O
,    O
which    O
suggests    O
a    O
role    O
of    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
.    O

S-Adenosylmethionine    B-Purine114706749
,    O
a    O
source    O
of    O
methyl    O
groups    O
in    O
many    O
biogenic    O
arsenic    O
compounds    O
.    O

"S"-Adenosyl    B-Purine114706749
methionine    I-Purine114706749
can    O
subsequently    O
methylate    O
the    O
amine    O
of    O
phosphatidylethanolamines    O
to    O
yield    O
phosphatidylcholines    O
.    O

18-deoxy-25-demethyl    O
herboxitriene    O
is    O
then    O
epoxidized    O
by    O
enzyeme    O
HerE    O
on    O
the    O
carbon    O
carbon    O
double    O
bond    O
between    O
C14    O
and    O
C15    O
,    O
oxidized    O
by    O
enzyme    O
HerG    O
on    O
C-18    O
and    O
eventually    O
methylated    O
by    O
enzyme    O
HerF    O
on    O
C25    O
to    O
herboxidiene    O
with    O
the    O
help    O
of    O
cofactor    O
SAM    B-Purine114706749
.    O

The    O
backbone    O
is    O
synthesized    O
through    O
the    O
addition    O
of    O
two    O
carbon    O
units    O
via    O
addition    O
of    O
acetate    O
units    O
from    O
acetyl-CoA    B-Purine114706749
The    O
5    O
methyl    O
groups    O
are    O
added    O
via    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
(    O
SAM    O
)    O
methylation    O
,    O
as    O
opposed    O
to    O
incorporation    O
of    O
propionate    O
(    O
instead    O
of    O
acetate    O
)    O
to    O
the    O
growing    O
compound    O
during    O
biosynthesis    O
.    O

For    O
example    O
,    O
"S"-adenosylmethionine    B-Purine114706749
acts    O
as    O
a    O
methylating    O
agent    O
in    O
biological    O
SN2    O
reactions    O
.    O

The    O
methyl    O
groups    O
transferred    O
to    O
create    O
ADMA    O
are    O
derived    O
from    O
the    O
methyl    O
group    O
donor    O
"S"-adenosylmethionine    B-Purine114706749
,    O
an    O
intermediate    O
in    O
the    O
metabolism    O
of    O
homocysteine    O
.    O

Abbreviations    O
:    O
S-Adenosyl-L-homocysteine    B-Purine114706749
(    O
SAH    O
)    O
,    O
S-adenosyl-L-methionine    B-Purine114706749
(    O
SAM    O
)    O
,    O
DNA    O
methyltransferase    O
(    O
DNA    O
MTase    O
)    O
,    O
Uracil    O
-    O
DNA    O
glycosylase    O
(    O
UNG    O
)    O
.    O

CBS    O
uses    O
the    O
cofactor    O
pyridoxal    O
-    O
phosphate    O
(    O
PLP    O
)    O
and    O
can    O
be    O
allosterically    O
regulated    O
by    O
effectors    O
such    O
as    O
the    O
ubiquitous    O
cofactor    O
S-adenosyl-L-methionine    B-Purine114706749
(    O
adoMet    O
)    O
.    O

This    O
inhibition    O
is    O
alleviated    O
by    O
binding    O
of    O
the    O
allosteric    O
effector    O
,    O
adoMet    B-Purine114706749
,    O
or    O
by    O
deletion    O
of    O
the    O
regulatory    O
domain    O
;    O
however    O
,    O
the    O
magnitude    O
of    O
the    O
effects    O
differ    O
.    O

In    O
analogy    O
with    O
other    O
β-replacement    O
enzymes    O
,    O
the    O
reaction    O
catalyzed    O
by    O
CBS    O
is    O
predicted    O
to    O
involve    O
a    O
series    O
of    O
adoMet    B-Purine114706749
-    O
bound    O
intermediates    O
.    O

This    O
alternative    O
metabolic    O
pathway    O
is    O
also    O
dependent    O
on    O
adoMet    B-Purine114706749
.    O

Allosteric    O
activation    O
of    O
CBS    O
by    O
adoMet    B-Purine114706749
determines    O
the    O
metabolic    O
fate    O
of    O
homocysteine    O
.    O

Mammalian    O
CBS    O
is    O
activated    O
2.5    O
-    O
5-fold    O
by    O
AdoMet    O
with    O
a    O
dissociation    O
constant    O
of    O
15    O
µM.    O
AdoMet    B-Purine114706749
is    O
an    O
allosteric    O
activator    O
that    O
increases    O
the    O
Vmax    O
of    O
the    O
CBS    O
reaction    O
but    O
does    O
not    O
affect    O
the    O
Km    O
for    O
the    O
substrates    O
.    O

A    O
common    O
functional    O
feature    O
of    O
the    O
mutations    O
in    O
the    O
CBS    O
domains    O
is    O
that    O
the    O
mutations    O
abolish    O
or    O
strongly    O
reduce    O
activation    O
by    O
adoMet    B-Purine114706749
.    O

S-Adenosyl-L-methionine    B-Purine114706749

famciclovir    B-Purine114706749
(    O
INN    O
)    O

Famvir    B-Purine114706749

More    O
recent    O
research    O
has    O
indicated    O
that    O
systemic    O
famciclovir    B-Purine114706749
is    O
effective    O
at    O
treating    O
this    O
infection    O
in    O
cats    O
without    O
the    O
side    O
effects    O
reported    O
with    O
other    O
anti    O
-    O
viral    O
agents    O
.    O

Purine    B-Purine114706749
analogue    I-Purine114706749
of    O
guanine    O
:    O
Aciclovir    B-Purine114706749
,    O
Famciclovir    B-Purine114706749
,    O
Ganciclovir    B-Purine114706749
,    O
Penciclovir    O
,    O
Valaciclovir    B-Purine114706749
,    O
Valganciclovir    B-Purine114706749

In    O
RNA    O
,    O
there    O
are    O
many    O
modified    O
bases    O
,    O
including    O
pseudouridine    O
(    O
Ψ    O
)    O
,    O
dihydrouridine    O
(    O
D    O
)    O
,    O
inosine    O
(    O
I    O
)    O
,    O
ribothymidine    O
(    O
rT    O
)    O
and    O
7-methylguanosine    B-Purine114706749
(    O
m7    O
G    O
)    O
.    O

7-Methylguanosine    B-Purine114706749

8-Bromoguanosine    B-Purine114706749
3',5'-cyclic    I-Purine114706749
monophosphate    I-Purine114706749
(    O
8-Br    O
-    O
cGMP    O
)    O

:    O
S-adenosyl-L-methionine    B-Purine114706749
+    O
guanine1516    O
in    O
16S    O
rRNA    O
S-adenosyl-L-homocysteine    B-Purine114706749
+    O
methylguanine    B-Purine114706749
in    O
16S    O
rRNA    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
DNA    O
containing    O
6-O-methylguanine    B-Purine114706749
and    O
protein    O
L    O
-    O
cysteine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
DNA    O
and    O
protein    O
S    O
-    O
methyl    O
-    O
L    O
-    O
cysteine    O
.    O

Adenosine    B-Purine114706749
thiamine    I-Purine114706749
diphosphate    I-Purine114706749
(    O
AThDP    O
)    O
,    O
or    O
thiaminylated    O
adenosine    O
diphosphate    O
(    O
ADP    O
)    O
is    O
a    O
naturally    O
occurring    O
thiamine    O
adenine    O
nucleotide    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
16-hydroxytabersonine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
16-methoxytabersonine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
5,8,13,13a    O
-    O
tetrahydrocolumbamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tetrahydropalmatine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
7-methylxanthine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
3,7-dimethylxanthine    B-Purine114706749
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
dimethyl    O
sulfide    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
trimethylsulfonium    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
thiol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
thioether    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
gamma    O
-    O
tocopherol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
alpha    O
-    O
tocopherol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
trans    O
-    O
aconitate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
(    O
E)-3-(methoxycarbonyl)pent-2-enedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
trans    O
-    O
aconitate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
(    O
E)-2-(methoxycarbonylmethyl)butenedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
5-methylaminomethyl-2-thiouridylic    O
acid    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
N1-methyladenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
N6-methyladenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
5-methylcytosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
N1-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
N2-Methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
N7-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
2'-O    O
-    O
methylguanosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tRNA    O
containing    O
uridine    O
at    O
position    O
54    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
tRNA    O
containing    O
ribothymidine    O
at    O
position    O
54    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
L    O
-    O
tryptophan    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
L-2-methyltryptophan    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
tyramine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
N    O
-    O
methyltyramine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
vitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
7-O    O
-    O
methylvitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
and    O
xanthotoxol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Purine114706749
and    O
O    O
-    O
methylxanthotoxol    O
.    O

DPD    O
is    O
produced    O
by    O
degradation    O
of    O
"S"-adenosylhomocysteine    B-Purine114706749
by    O
the    O
action    O
of    O
the    O
enzyme    O
"    O
S    O
"-    O
ribosylhomocysteinase    O
.    O

The    O
pathway    O
for    O
the    O
synthesis    O
of    O
creatineArg    O
-    O
Arginine    O
;    O
GATM    O
-    O
Glycine    O
amidinotransferase    O
;    O
GAMT    O
-    O
Guanidinoacetate    O
N    O
-    O
methyltransferase    O
;    O
Gly    O
-    O
Glycine    O
;    O
Met    O
-    O
Methionine    O
;    O
SAH    O
-    O
S-adenosyl    B-Purine114706749
homocysteine    I-Purine114706749
;    O
SAM    O
-    O
S-adenosyl    B-Purine114706749
methionine    I-Purine114706749
.    O

According    O
to    O
the    O
official    O
blog    O
of    O
Autism    O
Speaks    O
,    O
James    O
found    O
that    O
autistic    O
children    O
exhibit    O
abnormal    O
folate    O
metabolism    O
that    O
is    O
detectable    O
by    O
higher    O
levels    O
of    O
plasma    O
homocysteine    O
,    O
adenosine    O
,    O
and    O
S-adenosyl-L-homocysteine    B-Purine114706749
in    O
the    O
mothers    O
of    O
these    O
children    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-homocysteine    B-Purine114706749
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
inosyl    O
-    O
L    O
-    O
homocysteine    O
and    O
NH3    O
.    O

The    O
5    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl-CoA    B-Purine114706749
,    O
malonyl    O
-    O
CoA    O
,    O
NADPH    O
,    O
H+    O
,    O
and    O
S-adenosyl-L-methionine    B-Purine114706749
,    O
whereas    O
its    O
6    O
products    O
are    O
dihydromonacolin    O
L    O
,    O
CoA    O
,    O
CO2    O
,    O
NADP+    O
,    O
S-adenosyl-L-homocysteine    B-Purine114706749
,    O
and    O
H2O.    O

Abbreviations    O
:    O
S-Adenosyl-L-homocysteine    B-Purine114706749
(    O
SAH    O
)    O
,    O
S-adenosyl-L-methionine    B-Purine114706749
(    O
SAM    O
)    O
,    O
DNA    O
methyltransferase    O
(    O
DNA    O
MTase    O
)    O
,    O
Uracil    O
-    O
DNA    O
glycosylase    O
(    O
UNG    O
)    O
.    O

Drugs    O
:    O
diuretics    O
(    O
e.g.    O
,    O
thiazides    O
,    O
furosemide    O
)    O
,    O
gliptins    O
(    O
e.g.    O
,    O
vildagliptin    O
,    O
sitagliptin    O
,    O
saxagliptin    O
,    O
linagliptin    B-Purine114706749
)    O
,    O
tetracycline    O
,    O
sulfonamides    O
,    O
estrogens    O
,    O
azathioprine    O
and    O
mercaptopurine    O
,    O
pentamidine    O
,    O
salicylates    O
,    O
steroids    O
,    O
Depakote    O

linagliptin    B-Purine114706749
(    O
INN    O
)    O

Their    O
chemical    O
structures    O
are    O
closely    O
related    O
to    O
the    O
agelasine    B-Purine114706749
.    O

In    O
contrast    O
,    O
8-bromoadenosine    B-Purine114706749
3',5'-cyclic    I-Purine114706749
monophosphate    I-Purine114706749
(    O
8-bromo    O
-    O
cAMP    O
)    O
down    O
-    O
regulates    O
VLDLR    O
expression    O
.    O

If    O
there    O
is    O
sufficient    O
DNA    O
to    O
measure    O
both    O
mass    O
and    O
average    O
length    O
,    O
it    O
is    O
possible    O
to    O
determine    O
the    O
proper    O
amount    O
of    O
dATP    B-Purine114706749
to    O
be    O
added    O
to    O
generate    O
poly(dA    O
)    O
tails    O
90    O
to    O
200    O
nucleotides    O
long    O
.    O

It    O
is    O
a    O
mixture    O
of    O
disodium    B-Purine114706749
inosinate    I-Purine114706749
(    O
IMP    O
)    O
and    O
disodium    O
guanylate    O
(    O
GMP    O
)    O
and    O
is    O
often    O
used    O
where    O
a    O
food    O
already    O
contains    O
natural    O
glutamates    O
(    O
as    O
in    O
meat    O
extract    O
)    O
or    O
added    O
monosodium    O
glutamate    O
(    O
MSG    O
)    O
.    O

Disodium    B-Purine114706749
inosinate    I-Purine114706749
.    O

Disodium    B-Purine114706749
inosinate    I-Purine114706749
(    O
E631    B-Purine114706749
)    O
is    O
the    O
disodium    O
salt    O
of    O
inosinic    B-Purine114706749
acid    I-Purine114706749
with    O
the    O
chemical    O
formula    O
C10H11N4Na2O8P.    O
It    O
is    O
used    O
as    O
a    O
food    O
additive    O
and    O
often    O
found    O
in    O
instant    O
noodles    O
,    O
potato    O
chips    O
,    O
and    O
a    O
variety    O
of    O
other    O
snacks    O
.    O

Purine    B-Purine114706749
analogue    I-Purine114706749
of    O
guanine    O
:    O
Aciclovir    B-Purine114706749
,    O
Famciclovir    B-Purine114706749
,    O
Ganciclovir    B-Purine114706749
,    O
Penciclovir    O
,    O
Valaciclovir    B-Purine114706749
,    O
Valganciclovir    B-Purine114706749

In    O
terms    O
of    O
the    O
treatment    O
of    O
cytomegalovirus    O
retinitis    O
,    O
oral    O
valganciclovir    B-Purine114706749
,    O
intravenous    O
ganciclovir    B-Purine114706749
,    O
IV    O
foscarnet    O
,    O
and    O
IV    O
cidofovir    O
are    O
all    O
efficient    O
in    O
the    O
treatment    O
of    O
this    O
condition    O
.    O

The    O
patents    O
concern    O
the    O
use    O
of    O
thiopurine    B-Purine114706749
drugs    O
in    O
the    O
treatment    O
of    O
autoimmune    O
diseases    O
,    O
such    O
as    O
Crohn    O
's    O
disease    O
and    O
ulcerative    O
colitis    O
.    O

The    O
thiopurine    B-Purine114706749
drugs    O
are    O
purine    O
antimetabolites    O
widely    O
used    O
in    O
the    O
treatment    O
of    O
acute    O
lymphoblastic    O
leukemia    O
,    O
autoimmune    O
disorders    O
(    O
e.g.    O
,    O
Crohn    O
's    O
disease    O
,    O
rheumatoid    O
arthritis    O
)    O
,    O
and    O
organ    O
transplant    O
recipients    O
.    O

Carlos    B-Purine114706749
Miller    I-Purine114706749
,    O
American    O
botanist    O

In    O
connection    O
with    O
cytokinins    O
like    O
kinetin    B-Purine114706749
,    O
auxins    O
like    O
IBA    O
can    O
be    O
used    O
to    O
cause    O
the    O
formation    O
of    O
masses    O
of    O
undifferentiated    O
cells    O
called    O
callus    O
.    O

Forodesine    B-Purine114706749
(    O
INN    O
;    O
also    O
known    O
as    O
Immucillin    B-Purine114706749
H    I-Purine114706749
;    O
trade    O
names    O
Mundesine    B-Purine114706749
and    O
Fodosine    B-Purine114706749
)    O
is    O
a    O
transition    O
-    O
state    O
analog    O
inhibitor    O
of    O
purine    O
nucleoside    O
phosphorylase    O
studied    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
T    O
-    O
cell    O
acute    O
lymphoblastic    O
leukemia    O
(    O
T    O
-    O
ALL    O
)    O
and    O
for    O
treatment    O
of    O
B    O
-    O
cell    O
acute    O
lymphocytic    O
leukemia    O
(    O
B    O
-    O
ALL    O
)    O
.    O

8-Hydroxyguanosine    B-Purine114706749
is    O
a    O
nucleoside    O
which    O
is    O
an    O
oxidative    O
derivative    O
of    O
guanosine    O
.    O

Inborn    O
errors    O
of    O
purine    O
–    O
pyrimidine    O
metabolism    O
are    O
a    O
class    O
of    O
inborn    O
error    O
of    O
metabolism    O
disorders    O
specifically    O
affecting    O
purine    B-Purine114706749
metabolism    I-Purine114706749
and    O
pyrimidine    O
metabolism    O
.    O

This    O
enzyme    O
participates    O
in    O
purine    B-Purine114706749
metabolism    I-Purine114706749
.    O

This    O
enzyme    O
participates    O
in    O
pentose    O
phosphate    O
pathway    O
and    O
purine    B-Purine114706749
metabolism    I-Purine114706749
.    O

This    O
enzyme    O
participates    O
in    O
purine    B-Purine114706749
metabolism    I-Purine114706749
.    O

This    O
enzyme    O
participates    O
in    O
purine    B-Purine114706749
metabolism    I-Purine114706749
.    O

As    O
head    O
of    O
department    O
he    O
conducted    O
research    O
into    O
purine    B-Purine114706749
metabolism    I-Purine114706749
and    O
ketonuria    O
,    O
proving    O
in    O
1921    O
that    O
the    O
carcinogen    O
in    O
coal    O
was    O
a    O
cyclic    O
hydrocarbon    O
.    O

This    O
enzyme    O
participates    O
in    O
purine    B-Purine114706749
metabolism    I-Purine114706749
.    O

This    O
enzyme    O
participates    O
in    O
purine    B-Purine114706749
metabolism    I-Purine114706749
.    O

This    O
enzyme    O
participates    O
in    O
purine    B-Purine114706749
metabolism    I-Purine114706749
.    O

This    O
enzyme    O
participates    O
in    O
3    O
metabolic    O
pathways    O
:    O
purine    B-Purine114706749
metabolism    I-Purine114706749
,    O
selenoamino    O
acid    O
metabolism    O
,    O
and    O
sulfur    O
metabolism    O
.    O

This    O
enzyme    O
participates    O
in    O
purine    B-Purine114706749
metabolism    I-Purine114706749
.    O

PreQ1-III    O
riboswitches    O
are    O
a    O
class    O
of    O
riboswitches    O
that    O
bind    O
pre    O
-    O
queuosine1    O
(    O
PreQ1    O
)    O
,    O
a    O
precursor    O
to    O
the    O
modified    O
nucleoside    O
queuosine    B-Purine114706749
.    O

Cordycepin    B-Purine114706749
(    O
3'-deoxyadenosine    O
)    O

2,8-Dihydroxyadenine    B-Purine114706749

8-Azaguanine    O
is    O
a    O
purine    B-Purine114706749
analog    I-Purine114706749
with    O
the    O
chemical    O
formula    O
C4H4N6O.    O
It    O
has    O
been    O
widely    O
studied    O
for    O
its    O
biological    O
activity    O
.    O

As    O
a    O
purine    B-Purine114706749
analog    I-Purine114706749
,    O
it    O
is    O
a    O
synthetic    O
chemotherapy    O
agent    O
that    O
targets    O
lymphocytes    O
and    O
selectively    O
suppresses    O
the    O
immune    O
system    O
.    O

FC    O
(    O
fludarabine    B-Purine114706749
with    O
cyclophosphamide    O
)    O

FR    O
(    O
fludarabine    B-Purine114706749
with    O
rituximab    O
)    O

FCR    O
(    O
fludarabine    B-Purine114706749
,    O
cyclophosphamide    O
,    O
and    O
rituximab    O
)    O

Second    O
line    O
treatment    O
may    O
include    O
fludarabine    B-Purine114706749
,    O
combined    O
with    O
cyclophosphamide    O
and/or    O
mitoxantrone    O
,    O
usually    O
with    O
rituximab    O
.    O

It    O
was    O
approved    O
by    O
the    O
US    O
Food    O
and    O
Drug    O
Administration    O
for    O
CLL    O
patients    O
who    O
have    O
been    O
treated    O
with    O
alkylating    O
agents    O
and    O
who    O
have    O
failed    O
fludarabine    B-Purine114706749
therapy    O
.    O

In    O
1938    O
,    O
the    O
Austrian    O
ethologist    O
Karl    O
von    O
Frisch    O
made    O
his    O
first    O
report    O
on    O
the    O
existence    O
of    O
the    O
chemical    O
alarm    O
signal    O
known    O
as    O
Schreckstoff    B-Purine114706749
(    O
startle    O
/    O
shock    O
matter    O
)    O
in    O
minnows    O
.    O

Schreckstoff    B-Purine114706749
(    O
lit    O
.    O
"    O
scream    O
stuff    O
"    O
)    O
,    O
a    O
chemical    O
alarm    O
signal    O
emitted    O
by    O
fish    O

5-Hydroxyisourate    B-Purine114706749
is    O
a    O
molecule    O
with    O
a    O
formula    O
of    O
C5H4N4O4    O
and    O
molecular    O
weight    O
of    O
184.110    O
g    O
/    O
mol    O
.    O

Inosine-5′-monophosphate    B-Purine114706749
dehydrogenase    I-Purine114706749
(    O
IMPDH    O
)    O
is    O
a    O
purine    O
biosynthetic    O
enzyme    O
that    O
catalyzes    O
the    O
nicotinamide    O
adenine    O
dinucleotide    O
(    O
NAD)-dependent    O
oxidation    O
of    O
inosine    B-Purine114706749
monophosphate    I-Purine114706749
(    O
IMP    O
)    O
to    O
xanthosine    B-Purine114706749
monophosphate    I-Purine114706749
(    O
XMP    O
)    O
,    O
the    O
first    O
committed    O
and    O
rate    O
-    O
limiting    O
step    O
towards    O
the    O
"    O
de    O
novo    O
"    O
biosynthesis    O
of    O
guanine    O
nucleotides    O
from    O
IMP    O
.    O

2-Chloro-"N"6-cyclopentyladenosine    B-Purine114706749
(    O
CCPA    B-Purine114706749
)    O
is    O
a    O
specific    O
receptor    O
agonist    O
for    O
the    O
Adenosine    O
A1    O
receptor    O
.    O

If    O
the    O
correct    O
anticodon    O
binds    O
to    O
the    O
mRNA    O
codon    O
,    O
the    O
ribosome    O
changes    O
configuration    O
and    O
alters    O
the    O
geometry    O
of    O
the    O
GTPase    O
domain    O
of    O
EF    O
-    O
Tu    O
,    O
resulting    O
in    O
the    O
hydrolysis    O
of    O
the    O
GTP    O
associated    O
with    O
the    O
EF    O
-    O
Tu    O
to    O
GDP    B-Purine114706749
and    O
Pi    O
.    O

In    O
molecular    O
biology    O
,    O
Adenylosuccinate    O
synthase    O
(    O
or    O
adenylosuccinate    O
synthetase    O
)    O
is    O
an    O
enzyme    O
that    O
plays    O
an    O
important    O
role    O
in    O
purine    O
biosynthesis    O
,    O
by    O
catalysing    O
the    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
(    O
GTP)-dependent    O
conversion    O
of    O
inosine    B-Purine114706749
monophosphate    I-Purine114706749
(    O
IMP    O
)    O
and    O
aspartic    O
acid    O
to    O
guanosine    B-Purine114706749
diphosphate    I-Purine114706749
(    O
GDP    O
)    O
,    O
phosphate    O
and    O
N(6)-(1,2-dicarboxyethyl)-AMP    O
.    O

In    O
an    O
example    O
of    O
feedback    O
inhibition    O
,    O
ATase    O
is    O
inhibited    O
mainly    O
by    O
the    O
end    O
-    O
products    O
of    O
the    O
purine    O
synthesis    O
pathway    O
,    O
AMP    O
,    O
GMP    B-Purine114706749
,    O
ADP    O
,    O
and    O
GDP    B-Purine114706749
.    O

The    O
Gs    O
alpha    O
subunit    O
of    O
the    O
stimulated    O
G    O
protein    O
complex    O
exchanges    O
GDP    B-Purine114706749
for    O
GTP    B-Purine114706749
and    O
is    O
released    O
from    O
the    O
complex    O
.    O

When    O
the    O
50S    O
subunit    O
joins    O
,    O
it    O
hydrolyzes    O
GTP    B-Purine114706749
to    O
GDP    B-Purine114706749
and    O
Pi    O
,    O
causing    O
a    O
conformational    O
change    O
in    O
the    O
IF2    O
that    O
causes    O
IF2    O
to    O
release    O
and    O
allow    O
the    O
70S    O
subunit    O
to    O
form    O
.    O

Substrate    O
-    O
level    O
phosphorylation    O
is    O
a    O
metabolic    O
reaction    O
that    O
results    O
in    O
the    O
formation    O
of    O
ATP    O
or    O
GTP    B-Purine114706749
by    O
the    O
direct    O
transfer    O
of    O
a    O
phosphoryl    O
(    O
PO3    O
)    O
group    O
to    O
ADP    O
or    O
GDP    B-Purine114706749
from    O
another    O
phosphorylated    O
compound    O
.    O

EF    O
-    O
Ts    O
serves    O
as    O
the    O
guanine    O
nucleotide    O
exchange    O
factor    O
for    O
EF    O
-    O
Tu    O
(    O
elongation    O
factor    O
thermo    O
unstable    O
)    O
,    O
catalyzing    O
the    O
release    O
of    O
guanosine    B-Purine114706749
diphosphate    I-Purine114706749
from    O
EF    O
-    O
Tu    O
.    O

This    O
protein    O
recruits    O
a    O
small    O
GTPase    O
called    O
Sar1    O
(    O
think    O
of    O
Sar1    O
as    O
a    O
switch    O
,    O
it    O
is    O
active    O
when    O
bound    O
to    O
GTP    B-Purine114706749
and    O
inactive    O
when    O
it    O
hydrolyses    O
the    O
GTP    O
to    O
GDP    B-Purine114706749
)    O
.    O

In    O
the    O
activated    O
NMBR    O
/    O
G    O
-    O
protein    O
complex    O
,    O
there    O
occurs    O
an    O
exchange    O
of    O
GTP    B-Purine114706749
for    O
GDP    B-Purine114706749
bound    O
to    O
G-α    O
subunit    O
.    O

:    O
ATP    O
+    O
GMP    B-Purine114706749
ADP    O
+    O
GDP    B-Purine114706749

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
GMP    B-Purine114706749
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
GDP    B-Purine114706749
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Purine114706749
and    O
5-hydroxy    O
-    O
L    O
-    O
lysine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Purine114706749
and    O
5-phosphonooxy    O
-    O
L    O
-    O
lysine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    B-Purine114706749
and    O
alpha    O
-    O
D    O
-    O
mannose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GTP    B-Purine114706749
and    O
3-phospho    O
-    O
D    O
-    O
glycerate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
GDP    B-Purine114706749
and    O
3-phospho    O
-    O
D    O
-    O
glyceroyl    O
phosphate    O
.    O

Cladribine    B-Purine114706749
is    O
an    O
anti    O
-    O
neoplastic    O
agent    O
used    O
in    O
the    O
treatment    O
of    O
hairy    O
cell    O
leukemia    O
;    O
its    O
mechanism    O
of    O
action    O
is    O
inhibition    O
of    O
adenosine    O
deaminase    O
.    O

Cladribine    B-Purine114706749
and    O
clofarabine    O
are    O
two    O
other    O
drugs    O
being    O
investigated    O
in    O
MCL    O
.    O

Cladribine    B-Purine114706749
is    O
a    O
medication    O
used    O
to    O
treat    O
hairy    O
cell    O
leukemia    O
(    O
HCL    O
,    O
leukemic    O
reticuloendotheliosis    O
)    O
and    O
B    O
-    O
cell    O
chronic    O
lymphocytic    O
leukemia    O
.    O

Protein    O
recognition    O
at    O
the    O
receptor    O
uses    O
cAMP    B-Purine114706749
as    O
a    O
secondary    O
messenger    O
.    O

When    O
bound    O
,    O
the    O
receptor    O
couples    O
to    O
G    O
-    O
protein    O
alpha    O
subunit    O
,    O
activates    O
adenylyl    O
cyclase    O
,    O
and    O
increases    O
cAMP    B-Purine114706749
production    O
.    O

During    O
ovulation    O
,    O
the    O
surge    O
in    O
luteinizing    O
hormone    O
increases    O
cAMP    B-Purine114706749
which    O
increases    O
progesterone    O
and    O
PGF2α    O
production    O
.    O

Some    O
of    O
these    O
pathways    O
include    O
Rap    O
,    O
Erk1/2    O
,    O
MAPK    O
,    O
B    O
-    O
RAF    O
,    O
PI3-K    O
,    O
cAMP    B-Purine114706749
,    O
PKA    O
,    O
and    O
TORC2    O
that    O
are    O
activated    O
to    O
initiate    O
exocytosis    O
,    O
proinsulin    O
gene    O
expression    O
and    O
translation    O
,    O
increase    O
insulin    O
biosynthesis    O
,    O
and    O
genetically    O
increase    O
beta    O
cell    O
proliferation    O
and    O
neogenesis    O
.    O

Prostaglandin    O
E1    O
(    O
PGE1    O
)    O
is    O
a    O
platelet    O
inhibitor    O
that    O
causes    O
an    O
increase    O
in    O
cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
)    O
in    O
platelets    O
by    O
stimulating    O
adenylyl    O
cyclase    O
activity    O
.    O

In    O
"    O
Dictyostelium    O
"    O
,    O
aggregation    O
is    O
signalled    O
by    O
cAMP    B-Purine114706749
,    O
but    O
others    O
use    O
different    O
chemicals    O
.    O

The    O
mechanism    O
behind    O
the    O
aggregation    O
of    O
the    O
amoebae    O
relies    O
on    O
Cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
)    O
as    O
a    O
signal    O
molecule    O
.    O

By    O
comparison    O
,    O
"    O
N    O
"-    O
methyldopamine    O
also    O
had    O
no    O
effect    O
in    O
caudectomized    O
mice    O
at    O
≤    O
150    O
mg    O
/    O
kg    O
,    O
and    O
only    O
a    O
weak    O
effect    O
in    O
nigral    O
-    O
lesioned    O
rats    O
at    O
25    O
mg    O
/    O
kg    O
,    O
although    O
it    O
was    O
as    O
effective    O
as    O
dopamine    O
in    O
stimulating    O
cAMP    B-Purine114706749
in    O
the    O
adenylate    O
cyclase    O
assay    O
.    O

Upregulation    O
of    O
the    O
cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
)    O
signal    O
transduction    O
pathway    O
by    O
cAMP    O
response    O
element    O
binding    O
protein    O
(    O
CREB    O
)    O
,    O
a    O
gene    O
transcription    O
factor    O
,    O
in    O
the    O
nucleus    O
accumbens    O
is    O
a    O
common    O
mechanism    O
of    O
psychological    O
dependence    O
among    O
several    O
classes    O
of    O
drugs    O
of    O
abuse    O
.    O

When    O
stimulated    O
,    O
it    O
increases    O
cAMP    B-Purine114706749
levels    O
,    O
in    O
turn    O
leading    O
to    O
CREB    O
activation    O
.    O

The    O
α    O
subunit    O
is    O
thought    O
to    O
be    O
the    O
effector    O
region    O
responsible    O
for    O
stimulation    O
of    O
adenylate    O
cyclase    O
(    O
involved    O
the    O
generation    O
of    O
cAMP    B-Purine114706749
)    O
.    O

The    O
cyclic    O
nucleotide    O
phosphodiesterases    O
constitute    O
a    O
group    O
of    O
enzymes    O
that    O
destroy    O
the    O
cyclic    O
nucleotides    O
cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
)    O
and    O
cyclic    B-Purine114706749
guanosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cGMP    O
)    O
.    O

These    O
channels    O
are    O
also    O
sensitive    O
to    O
the    O
cyclic    O
nucleotides    O
cAMP    B-Purine114706749
and    O
cGMP    B-Purine114706749
,    O
which    O
alter    O
the    O
voltage    O
sensitivity    O
of    O
the    O
channel    O
’s    O
opening    O
.    O

Cyclic    O
nucleotide    O
-    O
gated    O
channels    O
:    O
This    O
family    O
of    O
channels    O
is    O
characterized    O
by    O
activation    O
by    O
either    O
intracellular    O
cAMP    B-Purine114706749
or    O
cGMP    B-Purine114706749
.    O

Transcription    O
of    O
the    O
"    O
lsr    O
"    O
operon    O
is    O
also    O
thought    O
to    O
be    O
inhibited    O
by    O
dihydroxyacetone    O
phosphate    O
(    O
DHAP    O
)    O
through    O
its    O
competitive    O
binding    O
to    O
LsrR.    O
Glyceraldehyde    O
3-phosphate    O
has    O
also    O
been    O
shown    O
to    O
inhibit    O
the    O
"    O
lsr    O
"    O
operon    O
through    O
cAMP    B-Purine114706749
-    O
CAPK    O
-    O
mediated    O
inhibition    O
.    O

The    O
following    O
table    O
gives    O
these    O
receptors    O
:    O
a    O
)    O
full    O
name    O
;    O
b    O
)    O
shortened    O
names    O
;    O
c    O
)    O
activating    O
prostanoids    O
(    O
presented    O
in    O
order    O
of    O
decreasing    O
potencies    O
)    O
;    O
d    O
)    O
time    O
-    O
honored    O
classification    O
as    O
contractile    O
(    O
i.e.    O
conracting    O
smooth    O
muscle    O
)    O
,    O
relaxant    O
(    O
i.e.    O
relaxing    O
smooth    O
muscle    O
)    O
,    O
or    O
inhibitory    O
(    O
i.e.    O
inhibiting    O
adenyl    O
cyclase    O
(    O
AC    O
)    O
production    O
of    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
[    O
cAMP    O
]    O
)    O
;    O
e    O
)    O
G    O
proteins    O
types    O
to    O
which    O
they    O
link    O
and    O
activate    O
,    O
i.e.    O
those    O
containing    O
the    O
Gs    O
alpha    O
subunit    O
,    O
Gi    O
alpha    O
subunit    O
,    O
Gq    O
alpha    O
subunit    O
and/or    O
G12    O
subunit    O
;    O
and    O
f    O
)    O
signaling    O
pathways    O
which    O
they    O
regulate    O
including    O
Adenyl    O
cyclase    O
which    O
when    O
activated    O
increases    O
cellular    O
cAMP    B-Purine114706749
and    O
when    O
inhibited    O
reduces    O
the    O
cellular    O
levels    O
of    O
this    O
secondary    O
messenger    O
;    O
Phosphoinositide    O
3-kinase    O
which    O
when    O
activated    O
is    O
responsible    O
for    O
forming    O
phosphatidylinositol    O
3-phosphate    O
,    O
phosphatidylinositol    O
(    O
3,4)-bisphosphate    O
,    O
and    O
phosphatidylinositol    O
(    O
3,4,5)-trisphosphate    O
secondary    O
messengers    O
;    O
Phospholipase    O
C    O
(    O
PLC    O
)    O
which    O
when    O
activated    O
is    O
responsible    O
for    O
forming    O
Inositol    O
trisphosphate    O
(    O
IP3    O
)    O
and    O
diacylglycerol    O
secondary    O
messengers    O
that    O
are    O
,    O
respectively    O
,    O
responsible    O
for    O
raising    O
the    O
levels    O
of    O
Ca2    O
+    O
in    O
the    O
cellular    O
cytosol    O
to    O
control    O
the    O
activity    O
of    O
Ca2    O
+    O
-cell    O
signaling    O
agents    O
and    O
for    O
activating    O
protein    O
kinase    O
C    O
(    O
PKC    O
)    O
secondary    O
messengers    O
;    O
and    O
Extracellular    O
signal    O
–    O
regulated    O
kinases    O
(    O
ERK    O
)    O
,    O
p38    O
mitogen    O
-    O
activated    O
protein    O
kinases    O
(    O
p38    O
Mpk    O
)    O
,    O
and    O
cAMP    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
which    O
when    O
activated    O
phosphorylate    O
and    O
thereby    O
influence    O
the    O
activity    O
of    O
key    O
proteins    O
that    O
govern    O
cell    O
function    O
.    O

First    O
isolated    O
as    O
a    O
nuclear    O
protein    O
that    O
binds    O
to    O
cAMP    B-Purine114706749
-    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
,    O
this    O
gene    O
is    O
now    O
known    O
to    O
play    O
critical    O
roles    O
in    O
embryonic    O
development    O
,    O
growth    O
control    O
,    O
and    O
homeostasis    O
by    O
coupling    O
chromatin    O
remodeling    O
to    O
transcription    O
factor    O
recognition    O
.    O

This    O
leads    O
to    O
inhibition    O
of    O
adenylyl    O
cyclase    O
and    O
lactose    O
permease    O
,    O
therefore    O
cAMP    B-Purine114706749
levels    O
are    O
low    O
and    O
lactose    O
can    O
not    O
be    O
transported    O
inside    O
the    O
bacteria    O
.    O

When    O
glucose    O
levels    O
are    O
low    O
the    O
phosphorylated    O
form    O
of    O
EIIA    O
accumulates    O
and    O
consequently    O
activates    O
the    O
enzyme    O
adenylyl    O
cyclase    O
,    O
which    O
will    O
produce    O
high    O
levels    O
of    O
cAMP    B-Purine114706749
.    O

Gram    O
positive    O
bacteria    O
such    O
as    O
"    O
Bacillus    O
subtilis    O
"    O
have    O
a    O
cAMP    B-Purine114706749
-    O
independent    O
catabolite    O
repression    O
mechanism    O
controlled    O
by    O
catabolite    O
control    O
protein    O
A    O
(    O
CcpA    O
)    O
.    O

In    O
particular    O
,    O
Gαs    O
stimulates    O
adenyl    O
cyclase    O
to    O
raise    O
cellular    O
levels    O
of    O
cAMP    B-Purine114706749
thereby    O
activating    O
PKA    O
;    O
PKA    O
activates    O
various    O
types    O
of    O
signaling    O
molecules    O
such    O
as    O
the    O
transcription    O
factor    O
CREB    O
which    O
lead    O
to    O
different    O
types    O
of    O
functional    O
responses    O
depending    O
on    O
cell    O
type    O
.    O

,    O
pathways    O
that    O
activate    O
phospholipase    O
C    O
to    O
convert    O
cellular    O
phospholipids    O
to    O
diacylglycerol    O
which    O
promotes    O
the    O
activation    O
of    O
certain    O
isoforms    O
of    O
protein    O
kinase    O
C    O
,    O
pathways    O
that    O
elevated    O
cellular    O
cytosolic    O
Ca2    O
+    O
which    O
thereby    O
regulate    O
Ca2    O
+    O
-sensitive    O
cell    O
signaling    O
molecules    O
,    O
and    O
pathways    O
that    O
inhibit    O
adenyl    O
cyclase    O
which    O
thereby    O
lowers    O
cellular    O
levels    O
of    O
cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
)    O
to    O
reduce    O
the    O
activity    O
of    O
cAMP    O
-    O
dependent    O
signaling    O
molecules    O
.    O

After    O
binding    O
to    O
calmodulin    O
,    O
cyaA    O
–    O
ACD    O
catalyzes    O
the    O
cyclization    O
of    O
AMP    O
into    O
cAMP    B-Purine114706749
.    O

"    O
Genetically    O
engineered    O
mice    O
"    O
:    O
Only    O
few    O
generated    O
mutant    O
lines    O
can    O
be    O
regarded    O
as    O
depression    O
models    O
,    O
for    O
example    O
,    O
α2A    O
adrenergic    O
receptor    O
knockout    O
mice    O
,    O
glucocorticoid    O
receptor    O
heterozygous    O
mice    O
,    O
and    O
cAMP    B-Purine114706749
response    O
element    O
-    O
binding    O
protein    O
overexpressing    O
mice    O
.    O

When    O
the    O
β2-agonist    O
binds    O
and    O
activates    O
the    O
β2-adrenoreceptor    O
intracellular    O
signaling    O
becomes    O
largely    O
affected    O
through    O
cyclic    O
adenosine    O
monophosphate    O
(    O
cAMP    B-Purine114706749
)    O
and    O
protein    O
kinase    O
A    O
(    O
PKA    O
)    O
.    O

1971    O
-    O
Earl    O
W.    O
Sutherland    O
(    O
Chair    O
of    O
Pharmacology    O
)    O
,    O
Nobel    O
Prize    O
in    O
Physiology    O
or    O
Medicine    O
,    O
for    O
establishing    O
identity    O
and    O
importance    O
of    O
cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
or    O
cyclic    O
AMP    O
in    O
regulation    O
of    O
cell    O
metabolism    O
.    O

Rodent    O
studies    O
have    O
consistently    O
shown    O
upregulation    O
of    O
the    O
3,    B-Purine114706749
5-cyclic    I-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
)    O
system    O
induced    O
by    O
different    O
types    O
of    O
chronic    O
but    O
not    O
acute    O
antidepressant    O
treatment    O
,    O
including    O
serotonin    O
and    O
norepinephrine    O
uptake    O
inhibitors    O
,    O
monoamine    O
oxidase    O
inhibitors    O
,    O
tricyclic    O
antidepressants    O
,    O
lithium    O
and    O
electroconvulsions    O
.    O

Cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
or    O
cyclic    O
AMP    O
)    O
is    O
a    O
second    O
messenger    O
that    O
has    O
been    O
implicated    O
in    O
facilitating    O
mushroom    O
body    O
calcium    O
influx    O
in    O
Drosophila    O
melanogaster    O
MBNs    O
.    O

In    O
a    O
classical    O
conditioning    O
paradigm    O
,    O
pairing    O
neuronal    O
depolarization    O
(    O
via    O
acetylcholine    O
application    O
to    O
represent    O
the    O
odor    O
or    O
CS    O
)    O
with    O
subsequent    O
dopamine    O
application    O
(    O
to    O
represent    O
the    O
shock    O
or    O
US    O
)    O
,    O
results    O
in    O
a    O
synergistic    O
increase    O
in    O
cAMP    B-Purine114706749
in    O
the    O
mushroom    O
body    O
lobes    O
.    O

This    O
AC    O
activation    O
increases    O
the    O
concentration    O
of    O
cAMP    B-Purine114706749
,    O
which    O
activates    O
PKA    O
.    O

For    O
example    O
,    O
the    O
cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(cAMP)    I-Purine114706749
and    O
protein    O
kinase    O
A    O
(    O
PKA    O
)    O
pathways    O
appear    O
to    O
participate    O
in    O
neuronal    O
allocation    O
.    O

When    O
activated    O
by    O
the    O
second    O
messengers    O
such    O
as    O
cAMP    B-Purine114706749
and    O
calcium    O
ions    O
,    O
enzymes    O
such    O
as    O
PKA    O
and    O
MAP    O
kinase    O
can    O
translocate    O
to    O
the    O
nucleus    O
and    O
phosphorylate    O
CREB    O
to    O
initiate    O
transcription    O
of    O
target    O
genes    O
.    O

In    O
decidual    O
cells    O
and    O
in    O
lymphocytes    O
the    O
distal    O
promoter    O
and    O
thus    O
prolactin    O
expression    O
is    O
stimulated    O
by    O
cAMP    B-Purine114706749
.    O

Resting    O
platelets    O
maintain    O
active    O
calcium    O
efflux    O
via    O
a    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
activated    O
calcium    O
pump    O
.    O

It    O
is    O
thought    O
that    O
regulation    O
of    O
argininosuccinate    O
synthetase    O
activity    O
in    O
arginine    O
synthesis    O
occurs    O
primarily    O
at    O
the    O
transcriptional    O
level    O
in    O
response    O
to    O
glucocorticoids    O
,    O
cAMP    B-Purine114706749
,    O
glucagon    O
,    O
and    O
insulin    O
.    O

Recently    O
,    O
it    O
has    O
been    O
noted    O
that    O
extrasynaptic    O
NMDA    O
receptor    O
activation    O
,    O
triggered    O
by    O
both    O
glutamate    O
exposure    O
or    O
hypoxic    O
/    O
ischemic    O
conditions    O
,    O
activate    O
a    O
CREB    O
(    O
cAMP    B-Purine114706749
response    O
element    O
binding    O
)    O
protein    O
shut    O
-    O
off    O
,    O
which    O
in    O
turn    O
caused    O
loss    O
of    O
mitochondrial    O
membrane    O
potential    O
and    O
apoptosis    O
.    O

He    O
elucidated    O
the    O
pleiotropic    O
functions    O
of    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
in    O
Escherichia    O
coli    O
and    O
elaborated    O
on    O
the    O
antitermination    O
and    O
antiparallel    O
transcription    O
and    O
transcription    O
termination    O
sites    O
of    O
Lambda    O
phage    O
.    O

A    O
number    O
of    O
other    O
small    O
molecules    O
can    O
compensate    O
for    O
the    O
ATP    O
-    O
induced    O
shift    O
in    O
equilibrium    O
conformation    O
and    O
reactivate    O
PFK    O
,    O
including    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
,    O
ammonium    O
ions    O
,    O
inorganic    O
phosphate    O
,    O
and    O
fructose-1,6-    O
and    O
-2,6-biphosphate    O
.    O

Cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
)    O

While    O
it    O
is    O
known    O
that    O
myosin    O
phosphatase    O
is    O
regulated    O
by    O
rho    O
-    O
associated    O
protein    O
kinases    O
,    O
there    O
is    O
current    O
debate    O
about    O
whether    O
other    O
molecules    O
,    O
such    O
as    O
arachidonic    O
acid    O
and    O
cAMP    B-Purine114706749
,    O
also    O
regulate    O
the    O
enzyme    O
.    O

Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
I    O
includes    O
GRM1    O
and    O
GRM5    O
and    O
these    O
receptors    O
have    O
been    O
shown    O
to    O
activate    O
phospholipase    O
C.    O
Group    O
II    O
includes    O
GRM2    O
(    O
this    O
receptor    O
)    O
and    O
GRM3    O
while    O
Group    O
III    O
includes    O
GRM4    O
,    O
GRM6    O
,    O
GRM7    O
and    O
GRM8    O
.    O
Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

Group    O
I    O
includes    O
GRM1    O
and    O
GRM5    O
and    O
these    O
receptors    O
have    O
been    O
shown    O
to    O
activate    O
phospholipase    O
C.    O
Group    O
II    O
includes    O
GRM2    O
and    O
GRM3    O
while    O
Group    O
III    O
includes    O
GRM4    O
,    O
GRM6    O
,    O
GRM7    O
and    O
GRM8    O
.    O
Group    O
II    O
and    O
III    O
receptors    O
are    O
linked    O
to    O
the    O
inhibition    O
of    O
the    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
cascade    O
but    O
differ    O
in    O
their    O
agonist    O
selectivities    O
.    O

cAMP    B-Purine114706749

The    O
5-HT7    O
receptor    O
is    O
a    O
member    O
of    O
the    O
GPCR    O
superfamily    O
of    O
cell    O
surface    O
receptors    O
and    O
is    O
activated    O
by    O
the    O
neurotransmitter    O
serotonin    O
(    O
5-hydroxytryptamine    O
,    O
5-HT    O
)    O
The    O
5-HT7    O
receptor    O
is    O
coupled    O
to    O
Gs    O
(    O
stimulates    O
the    O
production    O
of    O
the    O
intracellular    O
signaling    O
molecule    O
cAMP    B-Purine114706749
)    O
and    O
is    O
expressed    O
in    O
a    O
variety    O
of    O
human    O
tissues    O
,    O
particularly    O
in    O
the    O
brain    O
,    O
the    O
gastrointestinal    O
tract    O
,    O
and    O
in    O
various    O
blood    O
vessels    O
.    O

Gs    O
in    O
turn    O
activates    O
adenylate    O
cyclase    O
which    O
increases    O
intracellular    O
levels    O
of    O
the    O
second    O
messenger    O
cAMP    B-Purine114706749
.    O

Dipyridamole    O
inhibits    O
the    O
phosphodiesterase    O
enzymes    O
that    O
normally    O
break    O
down    O
cAMP    B-Purine114706749
(    O
increasing    O
cellular    O
cAMP    O
levels    O
and    O
blocking    O
the    O
platelet    O
aggregation    O
response    O
to    O
ADP    O
)    O
and/or    O
cGMP    B-Purine114706749
.    O

cAMP    B-Purine114706749
impairs    O
platelet    O
aggregation    O
and    O
also    O
causes    O
arteriolar    O
smooth    O
muscle    O
relaxation    O
.    O

Transcription    O
activation    O
requires    O
the    O
binding    O
of    O
adenosine    O
triphosphate    O
(    O
ATP    O
)    O
and    O
maltotriose    O
to    O
MalT    O
and    O
the    O
binding    O
of    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
to    O
the    O
dimer    O
of    O
CRP    O
.    O

JDP2    O
regulates    O
12-O    O
-    O
tetradecanoylphorbol-13-acetate    O
(    O
TPA    O
)    O
response    O
element    O
(    O
TRE)-    O
and    O
cAMP    B-Purine114706749
-    O
responsive    O
element    O
(    O
CRE)-dependent    O
transcription    O
.    O

The    O
rationale    O
for    O
use    O
of    O
these    O
drugs    O
was    O
their    O
ability    O
to    O
increase    O
intracellular    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
(    O
adenosine    O
monophosphate    O
)    O
levels    O
,    O
which    O
might    O
counteract    O
inflammatory    O
signaling    O
pathways    O
that    O
induce    O
endothelial    O
permeability    O
.    O

With    O
Robert    O
L.    O
Perlman    O
he    O
established    O
the    O
first    O
general    O
mechanism    O
of    O
positive    O
gene    O
regulation    O
in    O
bacteria    O
,    O
showing    O
that    O
cyclic    B-Purine114706749
AMP    I-Purine114706749
and    O
its    O
receptor    O
protein    O
CRP    O
(    O
cyclic    O
AMP    O
receptor    O
protein    O
)    O
positively    O
regulated    O
the    O
activity    O
of    O
many    O
genes    O
.    O

MT1302    O
encodes    O
an    O
adenylyl    O
cyclase    O
that    O
converts    O
ATP    O
to    O
cAMP    B-Purine114706749
,    O
the    O
expression    O
of    O
ncrMT1302    O
is    O
regulated    O
by    O
cAMP    O
and    O
pH.    O

Xanthosine    B-Purine114706749
5'-triphosphate    I-Purine114706749
(    O
XTP    B-Purine114706749
)    O
is    O
a    O
nucleotide    O
that    O
is    O
not    O
produced    O
by    O
-    O
and    O
has    O
no    O
known    O
function    O
in    O
-    O
living    O
cells    O
.    O

Queuine    B-Purine114706749

Adenosine    B-Purine114706749
thiamine    I-Purine114706749
triphosphate    I-Purine114706749
(    O
AThTP    O
)    O
or    O
thiaminylated    O
adenosine    O
triphosphate    O
has    O
recently    O
been    O
discovered    O
in    O
"    O
Escherichia    O
coli    O
"    O
,    O
where    O
it    O
accumulates    O
as    O
a    O
result    O
of    O
carbon    O
starvation    O
.    O

In    O
addition    O
,    O
analysis    O
of    O
residues    O
from    O
ceramic    O
vessels    O
has    O
found    O
traces    O
of    O
theobromine    B-Purine114706749
and    O
caffeine    O
in    O
early    O
formative    O
vessels    O
from    O
Puerto    O
Escondido    O
,    O
Honduras    O
(    O
1100–900    O
BC    O
)    O
and    O
in    O
middle    O
formative    O
vessels    O
from    O
Colha    O
,    O
Belize    O
(    O
600–400    O
BC    O
)    O
using    O
similar    O
techniques    O
to    O
those    O
used    O
to    O
extract    O
chocolate    O
residues    O
from    O
four    O
classic    O
period    O
(    O
around    O
400    O
AD    O
)    O
vessels    O
from    O
a    O
tomb    O
at    O
the    O
Maya    O
archaeological    O
site    O
of    O
Rio    O
Azul    O
.    O

Many    O
genes    O
were    O
identified    O
as    O
coding    O
for    O
flavonoids    O
,    O
aromatic    O
terpenes    O
,    O
theobromine    B-Purine114706749
and    O
many    O
other    O
metabolites    O
involved    O
in    O
cocoa    O
flavor    O
and    O
quality    O
traits    O
,    O
among    O
which    O
a    O
relatively    O
high    O
proportion    O
code    O
for    O
polyphenols    O
,    O
which    O
constitute    O
up    O
to    O
8%    O
of    O
cacao    O
pods    O
dry    O
weight    O
.    O

However    O
,    O
the    O
fruit    O
is    O
poisonous    O
,    O
containing    O
,    O
amongst    O
other    O
substances    O
,    O
the    O
alkaloids    O
theobromine    B-Purine114706749
and    O
caffeine    O
,    O
as    O
well    O
as    O
an    O
extremely    O
bitter    O
terpene    O
.    O

He    O
finished    O
second    O
to    O
the    O
French    O
colt    O
Trepan    O
,    O
but    O
was    O
awarded    O
the    O
race    O
when    O
the    O
winner    O
tested    O
positive    O
for    O
theobromine    B-Purine114706749
,    O
a    O
banned    O
substance    O
.    O

Fresh    O
leaves    O
contain    O
about    O
4%    O
caffeine    O
,    O
as    O
well    O
as    O
related    O
compounds    O
including    O
theobromine    B-Purine114706749
.    O

Other    O
alkaloids    O
possess    O
psychotropic    O
(    O
"    O
e.g.    O
"    O
psilocin    O
)    O
and    O
stimulant    O
activities    O
(    O
"    O
e.g.    O
"    O
cocaine    O
,    O
caffeine    O
,    O
nicotine    O
,    O
theobromine    B-Purine114706749
)    O
,    O
and    O
have    O
been    O
used    O
in    O
entheogenic    O
rituals    O
or    O
as    O
recreational    O
drugs    O
.    O

This    O
group    O
includes    O
terpene    O
-    O
like    O
and    O
steroid    O
-    O
like    O
alkaloids    O
,    O
as    O
well    O
as    O
purine    O
-    O
like    O
alkaloids    O
such    O
as    O
caffeine    O
,    O
theobromine    B-Purine114706749
,    O
theacrine    O
and    O
theophylline    O
.    O

Most    O
alkaloids    O
are    O
weak    O
bases    O
,    O
but    O
some    O
,    O
such    O
as    O
theobromine    B-Purine114706749
and    O
theophylline    O
,    O
are    O
amphoteric    O
.    O

The    O
active    O
ingredients    O
,    O
like    O
those    O
of    O
the    O
related    O
yerba    O
mate    O
and    O
guayusa    O
plants    O
,    O
are    O
actually    O
caffeine    O
and    O
theobromine    B-Purine114706749
,    O
and    O
the    O
vomiting    O
either    O
was    O
learned    O
or    O
resulted    O
from    O
the    O
great    O
quantities    O
in    O
which    O
they    O
drank    O
the    O
beverage    O
coupled    O
with    O
fasting    O
.    O

Content    O
verification    O
tests    O
yielded    O
the    O
presence    O
of    O
Theobromine    B-Purine114706749
,    O
an    O
essential    O
cocoa    O
component    O
;    O
chromatography    O
and    O
UV    O
tests    O
detected    O
ions    O
of    O
cocoa    O
's    O
chemical    O
components    O
.    O

6-Thioguanine    B-Purine114706749
(    O
6-TG    O
)    O

Thioguanine    B-Purine114706749
.    O

Thiouric    O
acid    O
,    O
more    O
accurately    O
called    O
6-thiouric    O
acid    O
,    O
is    O
a    O
main    O
inactive    O
metabolite    O
of    O
the    O
immunosuppressive    O
drugs    O
azathioprine    O
,    O
mercaptopurine    O
and    O
tioguanine    B-Purine114706749
.    O

Thioguanine    B-Purine114706749

fenethylline    B-Purine114706749

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    O
,    O
clobenzorex    O
,    O
D    O
-    O
deprenyl    O
,    O
dimethylamphetamine    O
,    O
ethylamphetamine    O
,    O
fencamine    O
,    O
fenethylline    B-Purine114706749
,    O
fenproporex    O
,    O
furfenorex    O
,    O
lisdexamfetamine    O
,    O
mefenorex    O
,    O
mesocarb    O
,    O
prenylamine    O
,    O
selegiline    O
,    O
and    O
tranylcypromine    O
.    O

In    O
2004    O
,    O
two    O
North    O
Korean    O
embassy    O
employees    O
were    O
caught    O
smuggling    O
150,000    O
tablets    O
of    O
Clonazepam    O
in    O
Egypt    O
,    O
and    O
in    O
that    O
same    O
year    O
,    O
embassy    O
employees    O
from    O
Bulgaria    O
were    O
arrested    O
in    O
Turkey    O
in    O
possession    O
of    O
over    O
500,000    O
tablets    O
of    O
Captagon    B-Purine114706749
(    O
the    O
brand    O
name    O
for    O
the    O
synthetic    O
stimulant    O
fenethylline    O
,    O
or    O
phenethylline    O
)    O
,    O
with    O
an    O
estimated    O
street    O
value    O
of    O
$    O
7    O
million    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosylmethioninamine    B-Purine114706749
and    O
propane-1,3-diamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
5'-methylthioadenosine    O
and    O
bis(3-aminopropyl)amine    O
.    O

Emapunil    B-Purine114706749

Liberine    B-Purine114706749
aka    O
O(2),1,9-trimethyluric    O
acid    O

Cyclic    B-Purine114706749
guanosine    I-Purine114706749
monophosphate    I-Purine114706749
.    O

They    O
serve    O
as    O
sources    O
of    O
chemical    O
energy    O
(    O
adenosine    O
triphosphate    O
and    O
guanosine    B-Purine114706749
triphosphate    I-Purine114706749
)    O
,    O
participate    O
in    O
cellular    O
signaling    O
(    O
cyclic    B-Purine114706749
guanosine    I-Purine114706749
monophosphate    I-Purine114706749
and    O
cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
)    O
,    O
and    O
are    O
incorporated    O
into    O
important    O
cofactors    O
of    O
enzymatic    O
reactions    O
(    O
coenzyme    O
A    O
,    O
flavin    O
adenine    O
dinucleotide    O
,    O
flavin    O
mononucleotide    O
,    O
and    O
nicotinamide    O
adenine    O
dinucleotide    O
phosphate    O
)    O
.    O

These    O
drugs    O
,    O
including    O
sildenafil    O
,    O
inhibit    O
the    O
action    O
of    O
the    O
phosphodiesterase    O
,    O
allowing    O
for    O
a    O
higher    O
concentration    O
of    O
cyclic    B-Purine114706749
GMP    I-Purine114706749
in    O
the    O
penis    O
when    O
it    O
is    O
physically    O
stimulated    O
.    O

This    O
response    O
is    O
mediated    O
by    O
the    O
release    O
of    O
nitric    O
oxide    O
(    O
NO    O
)    O
from    O
nerve    O
terminals    O
and    O
endothelial    O
cells    O
,    O
which    O
stimulates    O
the    O
synthesis    O
of    O
cyclic    B-Purine114706749
guanosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
more    O
commonly    O
known    O
as    O
cyclic    O
GMP    O
or    O
cGMP    O
)    O
in    O
smooth    O
muscle    O
cells    O
.    O

Transducin    O
removes    O
the    O
inhibition    O
from    O
cGMP    B-Purine114706749
Phosphodiesterase    O
,    O
which    O
leads    O
to    O
the    O
breakdown    O
of    O
cGMP    O
.    O

cyclic    B-Purine114706749
guanosine    I-Purine114706749
monophosphate    I-Purine114706749

In    O
addition    O
Dithranol    O
may    O
act    O
by    O
reducing    O
the    O
elevated    O
levels    O
of    O
cGMP    B-Purine114706749
that    O
occurs    O
in    O
psoriasis    O
.    O

It    O
is    O
believed    O
that    O
the    O
core    O
contains    O
common    O
structural    O
elements    O
that    O
are    O
important    O
for    O
the    O
hydrolysis    O
of    O
cAMP    B-Purine114706749
and    O
cGMP    B-Purine114706749
phosphodiester    O
bonds    O
.    O

At    O
first    O
,    O
the    O
PDE3s    O
were    O
purified    O
and    O
described    O
as    O
enzymes    O
that    O
hydrolyse    O
both    O
cGMP    B-Purine114706749
and    O
cAMP    B-Purine114706749
with    O
Km    O
values    O
between    O
0.1    O
–    O
0.8    O
µM.    O
However    O
the    O
Vmax    O
for    O
cAMP    B-Purine114706749
hydrolysis    O
is    O
4    O
–    O
10    O
times    O
higher    O
than    O
Vmax    O
for    O
cGMP    B-Purine114706749
hydrolysis    O
.    O

Hydrolysis    O
of    O
cAMP    B-Purine114706749
by    O
PDE3    O
isoforms    O
is    O
also    O
directly    O
inhibited    O
by    O
cGMP    B-Purine114706749
,    O
although    O
PDE3B    O
is    O
only    O
≈10%    O
as    O
sensitive    O
to    O
cGMP    B-Purine114706749
inhibition    O
as    O
PDE3A.    O

The    O
cyclic    O
nucleotide    O
phosphodiesterases    O
constitute    O
a    O
group    O
of    O
enzymes    O
that    O
destroy    O
the    O
cyclic    O
nucleotides    O
cyclic    B-Purine114706749
adenosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cAMP    O
)    O
and    O
cyclic    B-Purine114706749
guanosine    I-Purine114706749
monophosphate    I-Purine114706749
(    O
cGMP    O
)    O
.    O

These    O
channels    O
are    O
also    O
sensitive    O
to    O
the    O
cyclic    O
nucleotides    O
cAMP    B-Purine114706749
and    O
cGMP    B-Purine114706749
,    O
which    O
alter    O
the    O
voltage    O
sensitivity    O
of    O
the    O
channel    O
’s    O
opening    O
.    O

Cyclic    O
nucleotide    O
-    O
gated    O
channels    O
:    O
This    O
family    O
of    O
channels    O
is    O
characterized    O
by    O
activation    O
by    O
either    O
intracellular    O
cAMP    B-Purine114706749
or    O
cGMP    B-Purine114706749
.    O

Sodium    O
nitroprusside    O
and    O
nitroglycerin    O
function    O
by    O
causing    O
vasodilation    O
through    O
nitric    O
oxide    O
,    O
which    O
manipulates    O
cGMP    B-Purine114706749
levels    O
through    O
guanylate    O
cyclase    O
.    O

Dipyridamole    O
inhibits    O
the    O
phosphodiesterase    O
enzymes    O
that    O
normally    O
break    O
down    O
cAMP    B-Purine114706749
(    O
increasing    O
cellular    O
cAMP    O
levels    O
and    O
blocking    O
the    O
platelet    O
aggregation    O
response    O
to    O
ADP    O
)    O
and/or    O
cGMP    B-Purine114706749
.    O


